<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7022795/results/search/disease/results.xml">
  <result pre="doi: 10.3390/microorganisms8010085microorganisms-08-00085 : Review The Use of Antimalarial Drugs against" exact="Viral Infection" post="https://orcid.org/0000-0001-9241-9762D’AlessandroSarah1https://orcid.org/0000-0001-8881-898XScaccabarozziDiletta2SignoriniLucia1https://orcid.org/0000-0003-1566-0231PeregoFederica1IlboudoDenise P.3FerrantePasquale1https://orcid.org/0000-0002-3199-9369DelbueSerena1*[1], sarah.dalessandro@unimi.itlucia.signorini@unimi.itfederica.perego@unimi.itpasquale.ferrante@unimi.it[2], diletta.scaccabarozzi@unimi.it[3], denise.ilboudo@gmail.com *Correspondence: serena.delbue@unimi.it; Tel.: +39-02-50315070"/>
  <result pre="10.3390/microorganisms8010085microorganisms-08-00085 : Review The Use of Antimalarial Drugs against Viral" exact="Infection" post="https://orcid.org/0000-0001-9241-9762D’AlessandroSarah1https://orcid.org/0000-0001-8881-898XScaccabarozziDiletta2SignoriniLucia1https://orcid.org/0000-0003-1566-0231PeregoFederica1IlboudoDenise P.3FerrantePasquale1https://orcid.org/0000-0002-3199-9369DelbueSerena1*[1], sarah.dalessandro@unimi.itlucia.signorini@unimi.itfederica.perego@unimi.itpasquale.ferrante@unimi.it[2], diletta.scaccabarozzi@unimi.it[3], denise.ilboudo@gmail.com *Correspondence: serena.delbue@unimi.it; Tel.: +39-02-50315070"/>
  <result pre="license (http://creativecommons.org/licenses/by/4.0/). Abstract In recent decades, drugs used to treat" exact="malaria" post="infection have been shown to be beneficial for many"/>
  <result pre="(http://creativecommons.org/licenses/by/4.0/). Abstract In recent decades, drugs used to treat malaria" exact="infection" post="have been shown to be beneficial for many other"/>
  <result pre="been shown to be beneficial for many other diseases, including" exact="viral" post="infections. In particular, they have received special attention due"/>
  <result pre="antiviral drugs against new emerging viruses (i.e., HIV, dengue virus," exact="chikungunya" post="virus, Ebola virus, etc.) or against classic infections due"/>
  <result pre="dengue virus, chikungunya virus, Ebola virus, etc.) or against classic" exact="infections" post="due to drug-resistant viral strains (i.e., human cytomegalovirus). Here,"/>
  <result pre="Ebola virus, etc.) or against classic infections due to drug-resistant" exact="viral" post="strains (i.e., human cytomegalovirus). Here, we reviewed the in"/>
  <result pre="derivatives, aryl-aminoalcohols, aminoquinolines, and antimicrobial drugs. antimalarial drugs viruses emerging" exact="infections" post="1. Introduction Antimalarial drugs used for the treatment and"/>
  <result pre="Introduction Antimalarial drugs used for the treatment and prevention of" exact="malaria" post="are classified in a heterogenic group [1]. They are"/>
  <result pre="mechanisms of action, which are often still not elucidated, against" exact="malaria" post="parasites. Furthermore, due to the complexity of these molecules,"/>
  <result pre="used for the treatment of other pathologies, such as cancer," exact="autoimmune" post="diseases, and nonmalaria infectious diseases [2,3,4]. Moreover, the geographical"/>
  <result pre="of other pathologies, such as cancer, autoimmune diseases, and nonmalaria" exact="infectious diseases" post="[2,3,4]. Moreover, the geographical overlaps between malaria and viral-related"/>
  <result pre="and nonmalaria infectious diseases [2,3,4]. Moreover, the geographical overlaps between" exact="malaria" post="and viral-related diseases [5,6,7] have led to the consideration"/>
  <result pre="lack of new effective antiviral drugs and vaccines against many" exact="viral" post="infections has strengthened interest in the potential antiviral activity"/>
  <result pre="of new effective antiviral drugs and vaccines against many viral" exact="infections" post="has strengthened interest in the potential antiviral activity of"/>
  <result pre="diseases beyond malaria. ART derivatives are active against other parasites," exact="cancer" post="cells and viruses, although with lower potency, with effective"/>
  <result pre="active against other parasites, cancer cells and viruses, although with" exact="lower" post="potency, with effective concentration50s (EC50s) in the micromolar range,"/>
  <result pre="their anti-HCMV effect in a fibroblast cell model by measuring" exact="viral" post="DNA synthesis in cellular lysates. ART showed the lowest"/>
  <result pre="most active, with low toxicity, for the inhibition of the" exact="hepatitis" post="B virus (HBV), measured by hepatitis B surface antigen"/>
  <result pre="the inhibition of the hepatitis B virus (HBV), measured by" exact="hepatitis" post="B surface antigen (HBsAg) and DNA release in a"/>
  <result pre="E6 and E7 in an in vitro model of cervical" exact="carcinoma" post="[18]. These results partially confirmed the report by Disbrow"/>
  <result pre="of DHA on canine oral papillomavirus [19]. ART also inhibits" exact="hepatitis" post="C virus (HCV) replicon replication [20], and the effect"/>
  <result pre="an iron donor [21,22]. Finally, ART showed inhibition of human" exact="immunodeficiency" post="virus (HIV) replication, but the effect was not reproducible"/>
  <result pre="different in vitro cell models, such as fibroblasts [11,16,24] and" exact="tumor" post="cells [25,26]. Compared to other ART derivatives, AS had"/>
  <result pre="assay and luminescent/fluorescent methods based on the use of transgenic" exact="viral" post="strains [24,30,31]. In some cases, the effect of AS"/>
  <result pre="dissemination of virus to the salivary glands, the number of" exact="viral" post="genome copies, and virus titers in salivary glands. This"/>
  <result pre="association with valacyclovir was tested in a murine model of" exact="herpes" post="simplex virus encephalitis (HSE) to evaluate not only the"/>
  <result pre="was tested in a murine model of herpes simplex virus" exact="encephalitis" post="(HSE) to evaluate not only the antiviral but also"/>
  <result pre="also the immunomodulating activity, which would be beneficial in this" exact="disease" post="model. The survival rates of mice treated with both"/>
  <result pre="alone, but no significant difference was observed in the brain" exact="viral" post="loads. Levels of cytokines such as Interleukine (IL)-1β, IL-2,"/>
  <result pre="are contrasting. In a case report, a rapid decrease in" exact="viral" post="load was observed in a stem cell transplant recipient"/>
  <result pre="A third case report of a patient with multidrug-resistant HCMV" exact="infection" post="is difficult to interpret due to the complicated series"/>
  <result pre="of treatments after two hematopoietic stem cell transplantations and consequent" exact="acute" post="graft-versus-host disease episodes. In this patient, AS given in"/>
  <result pre="after two hematopoietic stem cell transplantations and consequent acute graft-versus-host" exact="disease" post="episodes. In this patient, AS given in association with"/>
  <result pre="HCMV infection. Two of these showed a decrease in the" exact="viral" post="load [13]. In another study, five transplanted patients infected"/>
  <result pre="a clinical study conducted on 494 Ugandan children treated for" exact="acute" post="malaria either with the ACT or with sulfadoxine–pyrimethamine plus"/>
  <result pre="clinical study conducted on 494 Ugandan children treated for acute" exact="malaria" post="either with the ACT or with sulfadoxine–pyrimethamine plus AQ."/>
  <result pre="low micromolar range against Epstein Barr virus (EBV) in both" exact="epithelial" post="cells and lymphocytes [50]. Antiviral activity against human herpes"/>
  <result pre="both epithelial cells and lymphocytes [50]. Antiviral activity against human" exact="herpes" post="virus-6 (HHV-6) was demonstrated not only in vitro [51]"/>
  <result pre="and are able to reactivate in immunosuppressed hosts, such as" exact="HIV-positive" post="patients or transplant recipients. JCPyV causes a rare and"/>
  <result pre="patients or transplant recipients. JCPyV causes a rare and fatal" exact="disease" post="known as progressive multifocal leukoencephalopathy (PML), while BKPyV is"/>
  <result pre="recipients. JCPyV causes a rare and fatal disease known as" exact="progressive multifocal leukoencephalopathy" post="(PML), while BKPyV is associated with nephropathy [56]. As"/>
  <result pre="causes a rare and fatal disease known as progressive multifocal" exact="leukoencephalopathy" post="(PML), while BKPyV is associated with nephropathy [56]. As"/>
  <result pre="as progressive multifocal leukoencephalopathy (PML), while BKPyV is associated with" exact="nephropathy" post="[56]. As mentioned above, ART and AS were more"/>
  <result pre="and small sample sizes preclude conclusions [59]. During the EBOV" exact="disease" post="epidemic in West Africa in 2014–2016, two mass drug"/>
  <result pre="a fibroblast model using a luminescent assay based on transgenic" exact="viral" post="strain. Compared to AS and/or ART, artemether was the"/>
  <result pre="antimalarial drug itself. DHA and ART were tested against bovine" exact="viral" post="diarrhea virus (BVDV), a surrogate in vitro model of"/>
  <result pre="drug itself. DHA and ART were tested against bovine viral" exact="diarrhea" post="virus (BVDV), a surrogate in vitro model of HCV,"/>
  <result pre="in children (6 months–10 years) coinfected with HCMV and malaria." exact="Viral" post="load in the urine decreased but only in high"/>
  <result pre="in the 17th century and has been used to treat" exact="malaria" post="since the early 1600s, currently still playing a pivotal"/>
  <result pre="first manuscript regarding the effect of quinine on influenza virus" exact="infections" post="in mice was published in 1946 [67]. Subsequently, in"/>
  <result pre="quinine sulfate has been conducted with other viruses, such as" exact="herpes" post="simplex virus-1 (HSV-1) and influenza A virus (IAV). Quinine"/>
  <result pre="vitro activity was also tested against IAV by means of" exact="viral" post="plaque inhibition assay, evaluating its prophylactic activity and showing"/>
  <result pre="with an EC50 within the micromolar range, depending on the" exact="viral" post="strains [70]. Recently, quinine sulfate was tested in vitro"/>
  <result pre="untreated control and a concentration-dependent reduction in DENV RNA and" exact="viral" post="proteins. The inhibition of replication was then confirmed for"/>
  <result pre="2009, Brickelmaier et al. chose MQ because of its high" exact="blood-brain barrier" post="penetration capability since it accumulates in brain tissue at"/>
  <result pre="EC50s within the low micromolar range [71]. Because of the" exact="absence of" post="a suitable animal model, this first paper represented the"/>
  <result pre="Although in 12 cases there was no progression of the" exact="disease" post="at follow-up [72,73,74,77,78,79,81,82,83,84,86,87], it is difficult to draw conclusions"/>
  <result pre="JCPyV entry into glial cells, preventing the diffusion of the" exact="infection" post="in oligodendrocytes. The outcomes of this treatment are controversial,"/>
  <result pre="and mirtazapine treatment [86,87,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105], and to the resolution of the" exact="infection" post="probably due to other factors [96,106,107,108,109] or to the"/>
  <result pre="reports have described the use of MQ by itself in" exact="HIV-positive" post="PML patients, sometimes with repression of JCPyV replication [122,123,124,125]"/>
  <result pre="[126]. The combined treatment MQ and mirtazapine was administered to" exact="HIV-positive" post="patients, leading to a failure because of premature death"/>
  <result pre="the PML itself [127,128]. One randomized study was conducted with" exact="HIV-positive" post="and HIV-negative patients, comparing the efficacy of the standard"/>
  <result pre="al. MQ showed different grades of efficacy, depending on the" exact="viral" post="strain and ranging from partial inhibition of replication to"/>
  <result pre="of efficacy, depending on the viral strain and ranging from" exact="partial" post="inhibition of replication to total ineffectiveness [70]. More recently,"/>
  <result pre="viral strain and ranging from partial inhibition of replication to" exact="total" post="ineffectiveness [70]. More recently, the effect of MQ on"/>
  <result pre="the Zika virus (ZIKV) in 2016, showing different reductions in" exact="infection" post="rate, depending on the cell model used, and different"/>
  <result pre="al. confirmed the in vitro effect of MQ on ZIKV" exact="infection" post="and evaluated it on DENV, performing several in vitro"/>
  <result pre="seen in the use of MQ as antiviral drug, its" exact="neurotoxicity" post="should be taken into account: when it is used"/>
  <result pre="should be taken into account: when it is used for" exact="malaria" post="prophylaxis, it is known to cause serious neuropsychiatric adverse"/>
  <result pre="ratio would look more favorable than for MQ used for" exact="malaria" post="chemoprophylaxis. 3.3. Halofantrine and Lumefantrine While good results were"/>
  <result pre="for halofantrine and lumefantrine, which failed in the inhibition of" exact="viral" post="replication, based on the few studies conducted to date."/>
  <result pre="as antimalarial drugs in wide areas where the resistance of" exact="malaria" post="parasites emerged. They are commonly used for connective tissue"/>
  <result pre="They are commonly used for connective tissue disorders, such as" exact="rheumatoid arthritis." post="Due to low toxicity and cost, high tolerability and"/>
  <result pre="CQ and hydroxyCQ have also been proposed for use against" exact="viral" post="infections. Even if their specific mechanisms in individual diseases"/>
  <result pre="and release by T cells: IL-1, 2, 6, or 18," exact="tumor" post="necrosis factor TNF-α and IFN-γ, reduced levels of chemokines"/>
  <result pre="particular, CQ/hydroxyCQ have been used for the treatment of emerging" exact="chikungunya" post="virus (CHIKV) infection, recently causing numerous outbreaks in the"/>
  <result pre="with different micromolar concentrations of CQ reduced virus yield and" exact="viral" post="RNA copy number [138]. De Lamballerie and colleagues confirmed"/>
  <result pre="of CQ was inversely related to the concentration of the" exact="viral" post="inoculum used, an unfavorable observation, considering the high viremia"/>
  <result pre="an unfavorable observation, considering the high viremia measured at the" exact="acute" post="stage of CHIKV infection (up to 1010 virus copies/mL"/>
  <result pre="considering the high viremia measured at the acute stage of" exact="CHIKV infection" post="(up to 1010 virus copies/mL serum) [37]. Sourisseau and"/>
  <result pre="the high viremia measured at the acute stage of CHIKV" exact="infection" post="(up to 1010 virus copies/mL serum) [37]. Sourisseau and"/>
  <result pre="the efficacy and safety of CQ for the treatment of" exact="CHIKV infection" post="in 2006 in French Reunion Island (Indian Ocean). No"/>
  <result pre="efficacy and safety of CQ for the treatment of CHIKV" exact="infection" post="in 2006 in French Reunion Island (Indian Ocean). No"/>
  <result pre="for the treatment of CHIKV infection in 2006 in French" exact="Reunion Island" post="(Indian Ocean). No significant difference was observed between the"/>
  <result pre="1) [37]. Aminoquinolines were proposed for the treatment of other" exact="viral" post="infections, such as ZIKV. In 2017, it was demonstrated"/>
  <result pre="CQ might be used to treat patients suspected of having" exact="dengue disease," post="avoiding the more severe form of dengue hemorrhagic fever"/>
  <result pre="of having dengue disease, avoiding the more severe form of" exact="dengue hemorrhagic fever" post="and/or shock. A clinical trial was also established to"/>
  <result pre="and an improvement in the well-being of patients with DENV" exact="infection" post="but did not alter the duration of the disease"/>
  <result pre="DENV infection but did not alter the duration of the" exact="disease" post="or the intensity and days of fever (Table 1)"/>
  <result pre="pigs did not protect the infected animals against the Ebola" exact="disease" post="[142]. Madrid and colleagues suggested that CQ could interfere"/>
  <result pre="clarify the efficacy of CQ in the treatment of filovirus" exact="infection" post="[144]. It was concluded that the efficacy of CQ"/>
  <result pre="and spread of coronavirus (CoV) in vitro and to prevent" exact="infection" post="with CoV in newborn mice. Since the suppressive effect"/>
  <result pre="or Huh-7 cells with CQ reduced HCV entry, replication, and" exact="infection" post="in a dose-dependent manner [148,149,150]. Furthermore, CQ, in combination"/>
  <result pre="hydroxyCQ and ribavirin, but no results were posted due to" exact="limited" post="recruitment. 4.3. Chloroquine and Hydroxychloroquine and HIV The anti-HIV-1"/>
  <result pre="et al. observed that CQ had a preventive role in" exact="HIV infection," post="reducing CD8 + T cell activation upon HIV replication"/>
  <result pre="to reduce the HIV-1 RNA plasma level, although at a" exact="lower" post="level than the antiviral zidovudine [40]. In contrast, the"/>
  <result pre="Paton and colleagues showed negative results, with an increase in" exact="viral" post="load and a decrease in CD4 number [41]. Another"/>
  <result pre="Minnesota. The results showed that the administration of CQ during" exact="chronic" post="HIV infection resulted in decreased immune activation, but no"/>
  <result pre="The results showed that the administration of CQ during chronic" exact="HIV infection" post="resulted in decreased immune activation, but no data regarding"/>
  <result pre="results showed that the administration of CQ during chronic HIV" exact="infection" post="resulted in decreased immune activation, but no data regarding"/>
  <result pre="of care with CQ prophylaxis compared to no prophylaxis in" exact="HIV-positive" post="patients in Malawi (Table 1) [44,45]. Chloroquine and Hydroxychloroquine"/>
  <result pre="patients were recruited. However, CQ was not shown to prevent" exact="infection" post="with IAV (Table 1) [38]. CQ had inhibitory effects"/>
  <result pre="potential of CQ as an antiviral in the treatment of" exact="hand, foot, and mouth disease" post="caused by EV infection. The positive results obtained in"/>
  <result pre="an antiviral in the treatment of hand, foot, and mouth" exact="disease" post="caused by EV infection. The positive results obtained in"/>
  <result pre="infection. The positive results obtained in the murine model of" exact="infection" post="were indicative of the fact that CQ may mitigate"/>
  <result pre="were indicative of the fact that CQ may mitigate the" exact="disease" post="severity in mammals [161]. 4.4. Amodiaquine and Emerging Viruses"/>
  <result pre="of DENV [162]. The time-course analysis suggested that AQ was" exact="stable" post="and that it reproducibly inhibited DENV infectivity. The data"/>
  <result pre="it reproducibly inhibited DENV infectivity. The data also showed that" exact="viral" post="entry and internalization were partially inhibited by the drug,"/>
  <result pre="the major effect occurred at a later stage of the" exact="viral" post="life cycle [162]. It is known that AQ inhibits"/>
  <result pre="study demonstrated that AQ was active against severe fever with" exact="thrombocytopenia" post="syndrome (SFTS) caused by SFTS virus (SFTSV) [163]. 4.5."/>
  <result pre="demonstrated that AQ was active against severe fever with thrombocytopenia" exact="syndrome" post="(SFTS) caused by SFTS virus (SFTSV) [163]. 4.5. Primaquine"/>
  <result pre="[163]. 4.5. Primaquine Primaquine was tested as an antiviral on" exact="primary" post="chicken embryo cells (CECs) infected by Newcastle disease virus"/>
  <result pre="an antiviral on primary chicken embryo cells (CECs) infected by" exact="Newcastle disease" post="virus [164]. It was demonstrated that primaquine had an"/>
  <result pre="antiviral on primary chicken embryo cells (CECs) infected by Newcastle" exact="disease" post="virus [164]. It was demonstrated that primaquine had an"/>
  <result pre="demonstrated that primaquine had an effect on the accumulation of" exact="viral" post="hemagglutinin on the cell surface. In addition, primaquine inhibited"/>
  <result pre="ability of atovaquone to reduce the infectivity of both a" exact="Brazilian" post="and a Ugandan strain of ZIKV by immunostaining the"/>
  <result pre="strain of ZIKV by immunostaining the envelope after treatment and" exact="infection" post="and subsequent plaque assay in different cells. These data"/>
  <result pre="a human placenta tissue model, with a dose-dependent reduction in" exact="infection" post="and virion production by the Ugandan strain [166]. 5.2."/>
  <result pre="doxycycline and sulfonamides, are widely used in the chemoprophylaxis of" exact="malaria" post="in all malaria areas [167]. It has been reported"/>
  <result pre="are widely used in the chemoprophylaxis of malaria in all" exact="malaria" post="areas [167]. It has been reported that these therapies"/>
  <result pre="these therapies could have activities beyond antimalarial activity, also against" exact="viral" post="infectious agents. Surprisingly, in many cases, the administration of"/>
  <result pre="therapies could have activities beyond antimalarial activity, also against viral" exact="infectious" post="agents. Surprisingly, in many cases, the administration of antibiotics"/>
  <result pre="antiviral agents showed significant antiviral activities against different types of" exact="viral" post="infections [168,169,170,171]. Despite this evidence, the antiviral mechanisms of"/>
  <result pre="agents showed significant antiviral activities against different types of viral" exact="infections" post="[168,169,170,171]. Despite this evidence, the antiviral mechanisms of action"/>
  <result pre="Doxycycline Doxycycline (DOX) is a semisynthetic tetracycline antibiotic that prevents" exact="bacterial" post="protein synthesis by acting on ribosomes (30S subunit) [167,172,173,174,175]."/>
  <result pre="with quinine for chemoprophylaxis in CQ-resistant P. falciparum cases of" exact="malaria" post="[176], has been shown to exert inhibitory effects against"/>
  <result pre="DOX significantly inhibited the proliferation of a panel of HPV-positive" exact="cervical cancer" post="cell lines, also inducing apoptosis of cervical cancer cells"/>
  <result pre="significantly inhibited the proliferation of a panel of HPV-positive cervical" exact="cancer" post="cell lines, also inducing apoptosis of cervical cancer cells"/>
  <result pre="of HPV-positive cervical cancer cell lines, also inducing apoptosis of" exact="cervical cancer" post="cells in a time- and dose-dependent manner [177]. Concerning"/>
  <result pre="HPV-positive cervical cancer cell lines, also inducing apoptosis of cervical" exact="cancer" post="cells in a time- and dose-dependent manner [177]. Concerning"/>
  <result pre="identify candidate antibiotics that can block the function of DENV" exact="viral" post="envelope proteins to prevent viral entry. Using an innovative"/>
  <result pre="block the function of DENV viral envelope proteins to prevent" exact="viral" post="entry. Using an innovative visual screening approach coupling computational"/>
  <result pre="viral envelope proteins to prevent viral entry. Using an innovative" exact="visual" post="screening approach coupling computational studies and biologic assays on"/>
  <result pre="reported that DOX inhibited DENV replication in vitro by reducing" exact="viral" post="protease activity and entry into host cells [168]. The"/>
  <result pre="demonstrating that the effect of DOX was directed more toward" exact="viral" post="entry than toward viral replication [169]. Furthermore, the inhibitory"/>
  <result pre="of DOX was directed more toward viral entry than toward" exact="viral" post="replication [169]. Furthermore, the inhibitory effect of DOX on"/>
  <result pre="the inhibitory effect of DOX on the replication of vesicular" exact="stomatitis" post="virus (VSV) in different stably infected cell lines was"/>
  <result pre="exerted its antiviral activity at the early-mid stage of VSV" exact="infection" post="[170]. These results indicated a different mode of action"/>
  <result pre="vivo study was published on IAV. Treatment with DOX attenuated" exact="acute" post="lung injury in mice infected with a virulent IAV"/>
  <result pre="that the antibiotic treatment was able to alleviate severe influenza" exact="pneumonia" post="symptoms [171]. It is, therefore, possible to conclude that"/>
  <result pre="as a potential antiviral agent in vitro, the mechanisms of" exact="viral" post="replication inhibition and the targeted virus species have yet"/>
  <result pre="and dihydrofolate reductase enzymes of bacteria (and protozoa) and inhibiting" exact="bacterial" post="growth [179,180]. The sulfadoxine-pyrimethamine combination is used in some"/>
  <result pre="is used in some settings for the treatment of uncomplicated" exact="malaria" post="in pregnant women, and it is the only drug"/>
  <result pre="combination on HIV replication. Experiments were conducted in vitro using" exact="peripheral" post="blood mononuclear cells, MT-2 cells, MT-4 cells, and a"/>
  <result pre="replication in MT-2 cells, while it inhibited HIV replication in" exact="peripheral" post="blood mononuclear cells [23]. Moreover, recent studies have demonstrated"/>
  <result pre="sulfonamides can act on latent herpesviruses, such as EBV and" exact="Kaposi sarcoma" post="herpesvirus (KSHV) [182,183]. Furthermore, a work conducted by Angius"/>
  <result pre="can act on latent herpesviruses, such as EBV and Kaposi" exact="sarcoma" post="herpesvirus (KSHV) [182,183]. Furthermore, a work conducted by Angius"/>
  <result pre="sulfonamide antibiotics suppressed the KSHV latent state in permanently infected" exact="lymphoma" post="cells [183]. This result suggested that sulfonamides might play"/>
  <result pre="that sulfonamides might play a potential role in clearing KSHV-infected" exact="lymphoma" post="cells. Since conventional antiherpes drugs are able to slightly"/>
  <result pre="cells. Since conventional antiherpes drugs are able to slightly suppress" exact="viral" post="replication in the lytic phase but do not clear"/>
  <result pre="aryl-aminoalcohols, the use of MQ in the treatment of JCPyV" exact="infection" post="has been extensive, although with contradictory outcomes. Among the"/>
  <result pre="of some emerging viruses, such as DENV and ZIKV. Emerging" exact="infections" post="have also been targeted by antibacterial drugs, such as"/>
  <result pre="Most of them regard the use of antimalarial drugs against" exact="HIV infection," post="but some of them failed, and for others, the"/>
  <result pre="ART Artemisinin AS Artesunate CHIKV Chikungunya virus CQ Chloroquine DENV" exact="Dengue" post="virus DHA Dihydroartemisinin EC50s Effective concentrations EBV Epstein-Barr virus"/>
  <result pre="virus DHA Dihydroartemisinin EC50s Effective concentrations EBV Epstein-Barr virus HBV" exact="Hepatitis" post="B virus HCMV Human cytomegalovirus HCV Hepatitis C virus"/>
  <result pre="Epstein-Barr virus HBV Hepatitis B virus HCMV Human cytomegalovirus HCV" exact="Hepatitis" post="C virus HPV Human papillomavirus hydroxyCQ hydroxychloroquine IL Interleukin"/>
  <result pre="HPV Human papillomavirus hydroxyCQ hydroxychloroquine IL Interleukin INF Interferon KSHV" exact="Kaposi sarcoma" post="herpesvirus MQ Mefloquine RCMV Rat cytomegalovirus TNF Tumor necrosis"/>
  <result pre="Human papillomavirus hydroxyCQ hydroxychloroquine IL Interleukin INF Interferon KSHV Kaposi" exact="sarcoma" post="herpesvirus MQ Mefloquine RCMV Rat cytomegalovirus TNF Tumor necrosis"/>
  <result pre="KSHV Kaposi sarcoma herpesvirus MQ Mefloquine RCMV Rat cytomegalovirus TNF" exact="Tumor" post="necrosis factor VSV Vesicular stomatitis virus ZIKV Zika virus"/>
  <result pre="Mefloquine RCMV Rat cytomegalovirus TNF Tumor necrosis factor VSV Vesicular" exact="stomatitis" post="virus ZIKV Zika virus References References 1.collab: World Health"/>
  <result pre="MalariaWorld Health OrganizationGeneva, Switzerland2015 2.HaładyjE.SikoraM.Felis-GiemzaA.OlesińskaM.Antimalarials—Are they effective and safe in" exact="rheumatic" post="diseases?Reumatologia20185616417310.5114/reum.2018.7690430042604 3.DasA.K.Anticancer Effect of AntiMalarial Artemisinin CompoundsAnn. Med. Health"/>
  <result pre="Med. Health Sci. Res.201559310210.4103/2141-9248.15360925861527 4.WolfR.TufanoM.A.RuoccoV.GrimaldiE.RuoccoE.DonnarummaG.BaroniA.Quinine sulfate inhibits invasion of some" exact="bacterial" post="skin pathogensInt. J. Dermatol.20064566166310.1111/j.1365-4632.2006.02696.x16796622 5.GwitiraI.MurwiraA.MberikunasheJ.MasochaM.Spatial overlaps in the distribution"/>
  <result pre="skin pathogensInt. J. Dermatol.20064566166310.1111/j.1365-4632.2006.02696.x16796622 5.GwitiraI.MurwiraA.MberikunasheJ.MasochaM.Spatial overlaps in the distribution of" exact="HIV/AIDS" post="and malaria in ZimbabweBMC Infect. Dis.20181859810.1186/s12879-018-3513-y30482166 6.SantanaV.O.S.LavezzoL.C.MondiniA.TerzianA.C.BronzoniR.V.RossitA.R.MachadoR.L.RahalP.NogueiraM.C.NogueiraM.L.Concurrent Dengue and"/>
  <result pre="J. Dermatol.20064566166310.1111/j.1365-4632.2006.02696.x16796622 5.GwitiraI.MurwiraA.MberikunasheJ.MasochaM.Spatial overlaps in the distribution of HIV/AIDS and" exact="malaria" post="in ZimbabweBMC Infect. Dis.20181859810.1186/s12879-018-3513-y30482166 6.SantanaV.O.S.LavezzoL.C.MondiniA.TerzianA.C.BronzoniR.V.RossitA.R.MachadoR.L.RahalP.NogueiraM.C.NogueiraM.L.Concurrent Dengue and malaria in"/>
  <result pre="distribution of HIV/AIDS and malaria in ZimbabweBMC Infect. Dis.20181859810.1186/s12879-018-3513-y30482166 6.SantanaV.O.S.LavezzoL.C.MondiniA.TerzianA.C.BronzoniR.V.RossitA.R.MachadoR.L.RahalP.NogueiraM.C.NogueiraM.L.Concurrent" exact="Dengue" post="and malaria in the Amazon regionRev. Soc. Bras. Med."/>
  <result pre="HIV/AIDS and malaria in ZimbabweBMC Infect. Dis.20181859810.1186/s12879-018-3513-y30482166 6.SantanaV.O.S.LavezzoL.C.MondiniA.TerzianA.C.BronzoniR.V.RossitA.R.MachadoR.L.RahalP.NogueiraM.C.NogueiraM.L.Concurrent Dengue and" exact="malaria" post="in the Amazon regionRev. Soc. Bras. Med. Trop.20104350851110.1590/S0037-8682201000050000721085859 7.SalamN.MustafaS.HafizA.ChaudharyA.A.DeebaF.ParveenS.Global"/>
  <result pre="a potent antiviral agent in a patient with late drug-resistant" exact="cytomegalovirus infection" post="after hematopoietic stem cell transplantationClin. Infect. Dis.2008461455145710.1086/58710618419454 13.WolfD.G.ShimoniA.ResnickI.B.StammingerT.NeumannA.U.ChouS.EfferthT.CaplanO.RoseJ.NaglerA.et al.Human"/>
  <result pre="potent antiviral agent in a patient with late drug-resistant cytomegalovirus" exact="infection" post="after hematopoietic stem cell transplantationClin. Infect. Dis.2008461455145710.1086/58710618419454 13.WolfD.G.ShimoniA.ResnickI.B.StammingerT.NeumannA.U.ChouS.EfferthT.CaplanO.RoseJ.NaglerA.et al.Human"/>
  <result pre="artemisinin derivativesJ. Antimicrob. Chemother.201469344010.1093/jac/dkt34624003183 17.RomeroM.R.EfferthT.SerranoM.A.CastañoB.MaciasR.I.BrizO.MarinJ.J.Effect of artemisinin/artesunate as inhibitors of" exact="hepatitis" post="B virus production in an &quot;in vitro&quot; replicative systemAntivir."/>
  <result pre="Telomerase Subunits and Induces Apoptosis in HPV-39 Infected Human Cervical" exact="Cancer" post="CellsJ. Cell. Biochem.20151161968198110.1002/jcb.2515225755006 19.DisbrowG.L.BaegeA.C.KierpiecK.A.YuanH.CentenoJ.A.ThibodeauxC.A.HartmannD.SchlegelR.Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial"/>
  <result pre="Cervical Cancer CellsJ. Cell. Biochem.20151161968198110.1002/jcb.2515225755006 19.DisbrowG.L.BaegeA.C.KierpiecK.A.YuanH.CentenoJ.A.ThibodeauxC.A.HartmannD.SchlegelR.Dihydroartemisinin is cytotoxic to papillomavirus-expressing" exact="epithelial" post="cells in vitro and in vivoCancer Res.200565108541086110.1158/0008-5472.CAN-05-121616322232 20.ObeidS.AlenJ.NguyenV.H.PhamV.C.MeulemanP.PannecouqueC.LeT.N.NeytsJ.DehaenW.PaeshuyseJ.Artemisinin analogues"/>
  <result pre="vivoCancer Res.200565108541086110.1158/0008-5472.CAN-05-121616322232 20.ObeidS.AlenJ.NguyenV.H.PhamV.C.MeulemanP.PannecouqueC.LeT.N.NeytsJ.DehaenW.PaeshuyseJ.Artemisinin analogues as potent inhibitors of in vitro" exact="hepatitis" post="C virus replicationPLoS ONE20138e8178310.1371/journal.pone.008178324349127 21.PaeshuyseJ.CoelmontL.VliegenI.Van hemelJ.VandenkerckhoveJ.PeysE.SasB.De ClercqE.NeytsJ.Hemin potentiates the"/>
  <result pre="inactivates the RNA polymerase NS5B and suppresses subgenomic replication of" exact="hepatitis" post="C VirusJ. Biol. Chem.20052809049905710.1074/jbc.M41268720015637067 23.OguaririR.M.AdelsbergerJ.W.BaselerM.W.ImamichiT.Evaluation of the effect of"/>
  <result pre="treated with artesunate exhibit reduced rates of proliferation and human" exact="cytomegalovirus infection" post="in vitroJ. Thorac. Dis.201571151115710.3978/j.issn.2072-1439.2015.07.0526380730 25.SchnepfN.CorvoJ.PorsM.J.MazeronM.C.Antiviral activity of ganciclovir and"/>
  <result pre="with artesunate exhibit reduced rates of proliferation and human cytomegalovirus" exact="infection" post="in vitroJ. Thorac. Dis.201571151115710.3978/j.issn.2072-1439.2015.07.0526380730 25.SchnepfN.CorvoJ.PorsM.J.MazeronM.C.Antiviral activity of ganciclovir and"/>
  <result pre="25.SchnepfN.CorvoJ.PorsM.J.MazeronM.C.Antiviral activity of ganciclovir and artesunate towards human cytomegalovirus in" exact="astrocytoma" post="cellsAntivir. Res.20118918618810.1016/j.antiviral.2010.12.00221167209 26.HeR.FormanM.MottB.T.VenkatadriR.PosnerG.H.Arav-BogerR.Unique and highly selective anticytomegalovirus activities of"/>
  <result pre="mutantsAntivir. Res.20119236436810.1016/j.antiviral.2011.07.01821843554 28.ReiterC.FröhlichT.ZeinoM.MarschallM.BahsiH.LeidenbergerM.FriedrichO.KappesB.HampelF.EfferthT.et al.New efficient artemisinin derived agents against human" exact="leukemia" post="cells, human cytomegalovirus and Plasmodium falciparum: 2nd generation 1,2,4-trioxane-ferrocene"/>
  <result pre="and antiviral activitiesBioorg. Med. Chem.2015235452545810.1016/j.bmc.2015.07.04826260339 32.MorèreL.AndouardD.LabrousseF.SaadeF.CallisteC.A.CotinS.AubardY.RawlinsonW.D.EsclaireF.HantzS.et al.Ex vivo model of" exact="congenital" post="cytomegalovirus infection and new combination therapiesPlacenta201536414710.1016/j.placenta.2014.11.00325479789 33.DrouotE.PiretJ.BoivinG.Artesunate demonstrates in"/>
  <result pre="antiviral activitiesBioorg. Med. Chem.2015235452545810.1016/j.bmc.2015.07.04826260339 32.MorèreL.AndouardD.LabrousseF.SaadeF.CallisteC.A.CotinS.AubardY.RawlinsonW.D.EsclaireF.HantzS.et al.Ex vivo model of congenital" exact="cytomegalovirus infection" post="and new combination therapiesPlacenta201536414710.1016/j.placenta.2014.11.00325479789 33.DrouotE.PiretJ.BoivinG.Artesunate demonstrates in vitro synergism"/>
  <result pre="activitiesBioorg. Med. Chem.2015235452545810.1016/j.bmc.2015.07.04826260339 32.MorèreL.AndouardD.LabrousseF.SaadeF.CallisteC.A.CotinS.AubardY.RawlinsonW.D.EsclaireF.HantzS.et al.Ex vivo model of congenital cytomegalovirus" exact="infection" post="and new combination therapiesPlacenta201536414710.1016/j.placenta.2014.11.00325479789 33.DrouotE.PiretJ.BoivinG.Artesunate demonstrates in vitro synergism"/>
  <result pre="35.CanivetC.MenasriaR.RhéaumeC.PiretJ.BoivinG.Valacyclovir combined with artesunate or rapamycin improves the outcome of" exact="herpes" post="simplex virus encephalitis in mice compared to antiviral therapy"/>
  <result pre="artesunate or rapamycin improves the outcome of herpes simplex virus" exact="encephalitis" post="in mice compared to antiviral therapy aloneAntivir. Res.201512310511310.1016/j.antiviral.2015.09.00726374952 36.BorgesM.C.CastroL.A.FonsecaB.A.Chloroquine"/>
  <result pre="use improves dengue-related symptomsMem. Inst. Oswaldo. Cruz.201310859659910.1590/S0074-0276201300050001023903975 37.De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.RoquesP.Le GrandR.On" exact="chikungunya" post="acute infection and chloroquine treatmentVector Borne Zoonotic Dis.2008883783910.1089/vbz.2008.004918620511 38.PatonN.I.LeeL.XuY.OoiE.E.CheungY.B.ArchuletaS.WongG.Wilder-SmithA.SmithA.W.Chloroquine"/>
  <result pre="improves dengue-related symptomsMem. Inst. Oswaldo. Cruz.201310859659910.1590/S0074-0276201300050001023903975 37.De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.RoquesP.Le GrandR.On chikungunya" exact="acute" post="infection and chloroquine treatmentVector Borne Zoonotic Dis.2008883783910.1089/vbz.2008.004918620511 38.PatonN.I.LeeL.XuY.OoiE.E.CheungY.B.ArchuletaS.WongG.Wilder-SmithA.SmithA.W.Chloroquine for"/>
  <result pre="dengue-related symptomsMem. Inst. Oswaldo. Cruz.201310859659910.1590/S0074-0276201300050001023903975 37.De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.RoquesP.Le GrandR.On chikungunya acute" exact="infection" post="and chloroquine treatmentVector Borne Zoonotic Dis.2008883783910.1089/vbz.2008.004918620511 38.PatonN.I.LeeL.XuY.OoiE.E.CheungY.B.ArchuletaS.WongG.Wilder-SmithA.SmithA.W.Chloroquine for influenza"/>
  <result pre="controlled trialLancet Infect. Dis.20111167768310.1016/S1473-3099(11)70065-221550310 39.SperberK.LouieM.KrausT.PronerJ.SapiraE.LinS.StecherV.MayerL.Hydroxychloroquine treatment of patients with human" exact="immunodeficiency" post="virus type 1Clin. Ther.19951762263610.1016/0149-2918(95)80039-58565026 40.SperberK.ChiangG.ChenH.RossW.ChusidE.GoncharM.ChowR.LirianoO.Comparison of hydroxychloroquine with zidovudine"/>
  <result pre="of hydroxychloroquine with zidovudine in asymptomatic patients infected with human" exact="immunodeficiency" post="virus type 1Clin. Ther.19971991392310.1016/S0149-2918(97)80045-89385480 41.PatonN.I.GoodallR.L.DunnD.T.FranzenS.Collaco-MoraesY.GazzardB.G.WilliamsI.G.FisherM.J.WinstonA.FoxJ.et al.Effects of hydroxychloroquine on"/>
  <result pre="1Clin. Ther.19971991392310.1016/S0149-2918(97)80045-89385480 41.PatonN.I.GoodallR.L.DunnD.T.FranzenS.Collaco-MoraesY.GazzardB.G.WilliamsI.G.FisherM.J.WinstonA.FoxJ.et al.Effects of hydroxychloroquine on immune activation and" exact="disease" post="progression among HIV-infected patients not receiving antiretroviral therapy: A"/>
  <result pre="Hum. Retrovir.20163263664710.1089/aid.2015.033626935044 43.MurrayS.M.DownC.M.BoulwareD.R.StaufferW.M.CavertW.P.SchackerT.W.BrenchleyJ.M.DouekD.C.Reduction of immune activation with chloroquine therapy during" exact="chronic" post="HIV infectionJ. Virol.201084120821208610.1128/JVI.01466-1020844049 44.RoutyJ.P.AngelJ.B.PatelM.KanagarathamC.RadziochD.KemaI.GilmoreN.AncutaP.SingerJ.JenabianM.A.Assessment of chloroquine as a modulator"/>
  <result pre="and failure of artesunate treatment in five transplant recipients with" exact="disease" post="caused by drug-resistant cytomegalovirusAntivir. Res.2014101576110.1016/j.antiviral.2013.10.01424184983 49.GanttS.HuangM.L.MagaretA.BuntsL.SelkeS.WaldA.RosenthalP.J.DorseyG.CasperC.An artesunate-containing antimalarial treatment"/>
  <result pre="therapeutic use of Artesunate in treatment of human herpesvirus 6B" exact="myocarditis" post="in a childJ. Clin. Virol.20135715716010.1016/j.jcv.2013.02.00523473961 53.NaesensL.BonnafousP.AgutH.De ClercqE.Antiviral activity of"/>
  <result pre="Chemother.2014586724673410.1128/AAC.03714-1425155602 55.SharmaB.N.MarschallM.HenriksenS.RinaldoC.H.Antiviral effects of artesunate on polyomavirus BK replication in" exact="primary" post="human kidney cellsAntimicrob. Agents Chemother.20145827928910.1128/AAC.01800-1324145549 56.CookL.PolyomavirusesMicrobiol. Spectr.2016410.1128/microbiolspec.DMIH2-0010-2015 57.DaiR.XiaoX.PengF.LiM.GongG.Artesunate, an"/>
  <result pre="of Mass Artesunate-Amodiaquine Distribution on Mortality of Patients With Ebola" exact="Virus Disease" post="During West African OutbreakOpen Forum Infect. Dis.20196ofz25010.1093/ofid/ofz25031281856 61.Arav-BogerR.HeR.ChiouC.J.LiuJ.WoodardL.RosenthalA.Jones-BrandoL.FormanM.PosnerG.Artemisinin-derived dimers"/>
  <result pre="Mass Artesunate-Amodiaquine Distribution on Mortality of Patients With Ebola Virus" exact="Disease" post="During West African OutbreakOpen Forum Infect. Dis.20196ofz25010.1093/ofid/ofz25031281856 61.Arav-BogerR.HeR.ChiouC.J.LiuJ.WoodardL.RosenthalA.Jones-BrandoL.FormanM.PosnerG.Artemisinin-derived dimers"/>
  <result pre="on Mortality of Patients With Ebola Virus Disease During West" exact="African" post="OutbreakOpen Forum Infect. Dis.20196ofz25010.1093/ofid/ofz25031281856 61.Arav-BogerR.HeR.ChiouC.J.LiuJ.WoodardL.RosenthalA.Jones-BrandoL.FormanM.PosnerG.Artemisinin-derived dimers have greatly improved"/>
  <result pre="63.BlazquezA.G.Fernandez-DolonM.Sanchez-VicenteL.MaestreA.D.Gomez-San MiguelA.B.AlvarezM.SerranoM.A.JansenH.EfferthT.MarinJ.J.et al.Novel artemisinin derivatives with potential usefulness against liver/colon" exact="cancer" post="and viral hepatitisBioorg. Med. Chem.2013214432444110.1016/j.bmc.2013.04.05923685181 64.Barger-KamateB.FormanM.SangareC.O.HaidaraA.S.MaigaH.VaidyaD.DjimdeA.Arav-BogerR.Effect of artemether-lumefantrine (Coartem)"/>
  <result pre="al.Novel artemisinin derivatives with potential usefulness against liver/colon cancer and" exact="viral" post="hepatitisBioorg. Med. Chem.2013214432444110.1016/j.bmc.2013.04.05923685181 64.Barger-KamateB.FormanM.SangareC.O.HaidaraA.S.MaigaH.VaidyaD.DjimdeA.Arav-BogerR.Effect of artemether-lumefantrine (Coartem) on cytomegalovirus"/>
  <result pre="hepatitisBioorg. Med. Chem.2013214432444110.1016/j.bmc.2013.04.05923685181 64.Barger-KamateB.FormanM.SangareC.O.HaidaraA.S.MaigaH.VaidyaD.DjimdeA.Arav-BogerR.Effect of artemether-lumefantrine (Coartem) on cytomegalovirus urine" exact="viral" post="load during and following treatment for malaria in childrenJ."/>
  <result pre="on cytomegalovirus urine viral load during and following treatment for" exact="malaria" post="in childrenJ. Clin. Virol.201677404510.1016/j.jcv.2016.02.00626895228 65.AchanJ.TalisunaA.O.ErhartA.YekaA.TibenderanaJ.K.BaliraineF.N.RosenthalP.J.D’AlessandroU.Quinine, an old anti-malarial drug"/>
  <result pre="dengue virus infectionVirus Res.201825517117810.1016/j.virusres.2018.07.01830055216 67.SeelerA.O.GraessleO.OttW.H.Effect of quinine on influenza virus" exact="infections" post="in miceJ. Infect. Dis.19467915615810.1093/infdis/79.2.15620273894 68.WolfR.BaroniA.GrecoR.CorradoF.RuoccoE.TufanoM.A.RuoccoV.Quinine sulfate and HSV replicationDermatol."/>
  <result pre="vitroAntimicrob. Agents Chemother.2009531840184910.1128/AAC.01614-0819258267 72.KishidaS.TanakaK.Mefloquine treatment in a patient suffering from" exact="progressive multifocal leukoencephalopathy" post="after umbilical cord blood transplantIntern. Med.2010492509251310.2169/internalmedicine.49.322721088359 73.GoftonT.E.Al-KhotaniA.O’FarrellB.AngL.C.McLachlanR.S.Mefloquine in the"/>
  <result pre="Chemother.2009531840184910.1128/AAC.01614-0819258267 72.KishidaS.TanakaK.Mefloquine treatment in a patient suffering from progressive multifocal" exact="leukoencephalopathy" post="after umbilical cord blood transplantIntern. Med.2010492509251310.2169/internalmedicine.49.322721088359 73.GoftonT.E.Al-KhotaniA.O’FarrellB.AngL.C.McLachlanR.S.Mefloquine in the"/>
  <result pre="umbilical cord blood transplantIntern. Med.2010492509251310.2169/internalmedicine.49.322721088359 73.GoftonT.E.Al-KhotaniA.O’FarrellB.AngL.C.McLachlanR.S.Mefloquine in the treatment of" exact="progressive multifocal" post="leukoencephalopathyJ. Neurol. Neurosurg. Psychiatry20118245245510.1136/jnnp.2009.19065220562463 74.BeppuM.KawamotoM.NukuzumaS.KoharaN.Mefloquine improved progressive multifocal leukoencephalopathy"/>
  <result pre="treatment of progressive multifocal leukoencephalopathyJ. Neurol. Neurosurg. Psychiatry20118245245510.1136/jnnp.2009.19065220562463 74.BeppuM.KawamotoM.NukuzumaS.KoharaN.Mefloquine improved" exact="progressive multifocal leukoencephalopathy" post="in a patient with systemic lupus erythematosusIntern. Med.2012511245124710.2169/internalmedicine.51.681022687798 75.KobayashiZ.AkazaM.NumasawaY.IshiharaS.TomimitsuH.NakamichiK.SaijoM.MorioT.ShimizuN.SanjoN.et"/>
  <result pre="progressive multifocal leukoencephalopathyJ. Neurol. Neurosurg. Psychiatry20118245245510.1136/jnnp.2009.19065220562463 74.BeppuM.KawamotoM.NukuzumaS.KoharaN.Mefloquine improved progressive multifocal" exact="leukoencephalopathy" post="in a patient with systemic lupus erythematosusIntern. Med.2012511245124710.2169/internalmedicine.51.681022687798 75.KobayashiZ.AkazaM.NumasawaY.IshiharaS.TomimitsuH.NakamichiK.SaijoM.MorioT.ShimizuN.SanjoN.et"/>
  <result pre="Psychiatry20118245245510.1136/jnnp.2009.19065220562463 74.BeppuM.KawamotoM.NukuzumaS.KoharaN.Mefloquine improved progressive multifocal leukoencephalopathy in a patient with" exact="systemic" post="lupus erythematosusIntern. Med.2012511245124710.2169/internalmedicine.51.681022687798 75.KobayashiZ.AkazaM.NumasawaY.IshiharaS.TomimitsuH.NakamichiK.SaijoM.MorioT.ShimizuN.SanjoN.et al.Failure of mefloquine therapy in"/>
  <result pre="74.BeppuM.KawamotoM.NukuzumaS.KoharaN.Mefloquine improved progressive multifocal leukoencephalopathy in a patient with systemic" exact="lupus" post="erythematosusIntern. Med.2012511245124710.2169/internalmedicine.51.681022687798 75.KobayashiZ.AkazaM.NumasawaY.IshiharaS.TomimitsuH.NakamichiK.SaijoM.MorioT.ShimizuN.SanjoN.et al.Failure of mefloquine therapy in progressive"/>
  <result pre="systemic lupus erythematosusIntern. Med.2012511245124710.2169/internalmedicine.51.681022687798 75.KobayashiZ.AkazaM.NumasawaY.IshiharaS.TomimitsuH.NakamichiK.SaijoM.MorioT.ShimizuN.SanjoN.et al.Failure of mefloquine therapy in" exact="progressive multifocal" post="leukoencephalopathy: Report of two Japanese patients without human immunodeficiency"/>
  <result pre="progressive multifocal leukoencephalopathy: Report of two Japanese patients without human" exact="immunodeficiency" post="virus infectionJ. Neurol. Sci.201332419019410.1016/j.jns.2012.11.00423182496 76.RamadhaniP.BramantonoB.SedanaM.P.A Chronic Lymphocytic Leukemia Patient"/>
  <result pre="Japanese patients without human immunodeficiency virus infectionJ. Neurol. Sci.201332419019410.1016/j.jns.2012.11.00423182496 76.RamadhaniP.BramantonoB.SedanaM.P.A" exact="Chronic" post="Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by"/>
  <result pre="without human immunodeficiency virus infectionJ. Neurol. Sci.201332419019410.1016/j.jns.2012.11.00423182496 76.RamadhaniP.BramantonoB.SedanaM.P.A Chronic Lymphocytic" exact="Leukemia" post="Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham"/>
  <result pre="virus infectionJ. Neurol. Sci.201332419019410.1016/j.jns.2012.11.00423182496 76.RamadhaniP.BramantonoB.SedanaM.P.A Chronic Lymphocytic Leukemia Patient with" exact="Progressive" post="Multifocal Leukoencephalopathy Caused by John Cunningham VirusActa Med. Indones.20185015115829950535"/>
  <result pre="Neurol. Sci.201332419019410.1016/j.jns.2012.11.00423182496 76.RamadhaniP.BramantonoB.SedanaM.P.A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal" exact="Leukoencephalopathy" post="Caused by John Cunningham VirusActa Med. Indones.20185015115829950535 77.NishiyamaS.MisuT.Shishido-HaraY.NakamichiK.SaijoM.TakaiY.TakeiK.YamamotoN.KurodaH.SaitoR.et al.Fingolimod-associated"/>
  <result pre="mild IRIS in MS: A clinicopathologic studyNeurol. Neuroimmunol. NeuroInflamm.20185e41510.1212/NXI.000000000000041529725611 78.IshiiJ.Shishido-HaraY.KawamotoM.FujiwaraS.ImaiY.NakamichiK.KoharaN.A" exact="Punctate" post="Magnetic Resonance Imaging Pattern in a Patient with Systemic"/>
  <result pre="78.IshiiJ.Shishido-HaraY.KawamotoM.FujiwaraS.ImaiY.NakamichiK.KoharaN.A Punctate Magnetic Resonance Imaging Pattern in a Patient with" exact="Systemic" post="Lupus Erythematosus Is an Early Sign of Progressive Multifocal"/>
  <result pre="Punctate Magnetic Resonance Imaging Pattern in a Patient with Systemic" exact="Lupus Erythematosus" post="Is an Early Sign of Progressive Multifocal Leukoencephalopathy: A"/>
  <result pre="Patient with Systemic Lupus Erythematosus Is an Early Sign of" exact="Progressive" post="Multifocal Leukoencephalopathy: A Clinicopathological StudyIntern. Med.2018572727273410.2169/internalmedicine.0696-1729709947 79.DubeyD.ZhangY.GravesD.DeSenaA.D.FrohmanE.GreenbergB.Use of interleukin-2"/>
  <result pre="Clinicopathological StudyIntern. Med.2018572727273410.2169/internalmedicine.0696-1729709947 79.DubeyD.ZhangY.GravesD.DeSenaA.D.FrohmanE.GreenbergB.Use of interleukin-2 for management of natalizumab-associated" exact="progressive multifocal" post="leukoencephalopathy: Case report and review of literatureTher. Adv. Neurol."/>
  <result pre="report and review of literatureTher. Adv. Neurol. Disord.2016921121510.1177/175628561562102927134676 80.SanoY.NakanoY.OmotoM.TakaoM.IkedaE.OgaA.NakamichiK.SaijoM.MaokaT.SanoH.et al.Rituximab-associated" exact="progressive multifocal leukoencephalopathy" post="derived from non-Hodgkin lymphoma: Neuropathological findings and results of"/>
  <result pre="review of literatureTher. Adv. Neurol. Disord.2016921121510.1177/175628561562102927134676 80.SanoY.NakanoY.OmotoM.TakaoM.IkedaE.OgaA.NakamichiK.SaijoM.MaokaT.SanoH.et al.Rituximab-associated progressive multifocal" exact="leukoencephalopathy" post="derived from non-Hodgkin lymphoma: Neuropathological findings and results of"/>
  <result pre="treatmentIntern. Med.20155496597010.2169/internalmedicine.54.230825876582 81.GarroteH.de la FuenteA.OñaR.RodríguezI.EchevarríaJ.E.SepúlvedaJ.M.GarcíaJ.F.Long-term survival in a patient with" exact="progressive multifocal leukoencephalopathy" post="after therapy with rituximab, fludarabine and cyclophosphamide for chronic"/>
  <result pre="81.GarroteH.de la FuenteA.OñaR.RodríguezI.EchevarríaJ.E.SepúlvedaJ.M.GarcíaJ.F.Long-term survival in a patient with progressive multifocal" exact="leukoencephalopathy" post="after therapy with rituximab, fludarabine and cyclophosphamide for chronic"/>
  <result pre="multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for" exact="chronic" post="lymphocytic leukemiaExp. Hematol. Oncol.20154810.1186/s40164-015-0003-425767742 82.YoshidaT.KawamotoM.TogoM.KoharaN.ItoT.NakamichiK.SaijoM.MizunoT.Progressive multifocal leukoencephalopathy developing after"/>
  <result pre="and cyclophosphamide for chronic lymphocytic leukemiaExp. Hematol. Oncol.20154810.1186/s40164-015-0003-425767742 82.YoshidaT.KawamotoM.TogoM.KoharaN.ItoT.NakamichiK.SaijoM.MizunoT.Progressive multifocal" exact="leukoencephalopathy" post="developing after liver transplantation showing marked neurological symptom improvement"/>
  <result pre="findings: A case reportJ. Neurol. Sci.20153591310.1016/j.jns.2015.10.02826671076 83.HirayamaM.NosakiY.MatsuiK.TeraoS.KuwayamaM.TateyamaH.YoshidaM.HashizumeY.Efficacy of mefloquine to" exact="progressive multifocal leukoencephalopathy" post="initially presented with parkinsonismClin. Neurol. Neurosurg.201211472873110.1016/j.clineuro.2011.12.01022209147 84.ShinJ.W.JungK.H.LeeS.T.MoonJ.LimJ.A.ByunJ.I.ParkK.I.LeeS.K.ChuK.Mefloquine improved progressive"/>
  <result pre="case reportJ. Neurol. Sci.20153591310.1016/j.jns.2015.10.02826671076 83.HirayamaM.NosakiY.MatsuiK.TeraoS.KuwayamaM.TateyamaH.YoshidaM.HashizumeY.Efficacy of mefloquine to progressive multifocal" exact="leukoencephalopathy" post="initially presented with parkinsonismClin. Neurol. Neurosurg.201211472873110.1016/j.clineuro.2011.12.01022209147 84.ShinJ.W.JungK.H.LeeS.T.MoonJ.LimJ.A.ByunJ.I.ParkK.I.LeeS.K.ChuK.Mefloquine improved progressive"/>
  <result pre="multifocal leukoencephalopathy initially presented with parkinsonismClin. Neurol. Neurosurg.201211472873110.1016/j.clineuro.2011.12.01022209147 84.ShinJ.W.JungK.H.LeeS.T.MoonJ.LimJ.A.ByunJ.I.ParkK.I.LeeS.K.ChuK.Mefloquine improved" exact="progressive multifocal leukoencephalopathy" post="in a patient with immunoglobulin A nephropathyJ. Clin. Neurosci.2014211661166410.1016/j.jocn.2013.12.03124874696"/>
  <result pre="initially presented with parkinsonismClin. Neurol. Neurosurg.201211472873110.1016/j.clineuro.2011.12.01022209147 84.ShinJ.W.JungK.H.LeeS.T.MoonJ.LimJ.A.ByunJ.I.ParkK.I.LeeS.K.ChuK.Mefloquine improved progressive multifocal" exact="leukoencephalopathy" post="in a patient with immunoglobulin A nephropathyJ. Clin. Neurosci.2014211661166410.1016/j.jocn.2013.12.03124874696"/>
  <result pre="a patient with immunoglobulin A nephropathyJ. Clin. Neurosci.2014211661166410.1016/j.jocn.2013.12.03124874696 85.GourineniV.C.JuvetT.KumarY.BordeaD.SenaK.N.Progressive multifocal" exact="leukoencephalopathy" post="in a 62-year-old immunocompetent womanCase Rep. Neurol. Med.2014201454927110.1155/2014/54927124711940 86.ShiraiS.YabeI.KanoT.ShimizuY.SasamoriT.SatoK.HirotaniM.NonakaT.TakahashiI.MatsushimaM.et"/>
  <result pre="86.ShiraiS.YabeI.KanoT.ShimizuY.SasamoriT.SatoK.HirotaniM.NonakaT.TakahashiI.MatsushimaM.et al.Usefulness of 11C-methionine-positron emission tomography for the diagnosis of" exact="progressive multifocal" post="leukoencephalopathyJ. Neurol.20142612314231810.1007/s00415-014-7500-y25223960 87.MitsikostasD.D.MastorodemosV.TsagournizakisM.KodounisA.TsagkaropoulosA.KonitsiotisS.ToulasP.PapadimitriouA.PapadimitriouD.TavernarakisA.et al.Natalizumab-related progressive multifocal leukoencephalopathy in GreeceMult."/>
  <result pre="for the diagnosis of progressive multifocal leukoencephalopathyJ. Neurol.20142612314231810.1007/s00415-014-7500-y25223960 87.MitsikostasD.D.MastorodemosV.TsagournizakisM.KodounisA.TsagkaropoulosA.KonitsiotisS.ToulasP.PapadimitriouA.PapadimitriouD.TavernarakisA.et al.Natalizumab-related" exact="progressive multifocal leukoencephalopathy" post="in GreeceMult. Scler. Relat. Disord.2014320321010.1016/j.msard.2013.08.00625878008 88.Sanchez-QuintanaA.Breña-AtienzaJ.Marrero-SantosC.Alvarez-AcostaL.Late relapse of progressive"/>
  <result pre="diagnosis of progressive multifocal leukoencephalopathyJ. Neurol.20142612314231810.1007/s00415-014-7500-y25223960 87.MitsikostasD.D.MastorodemosV.TsagournizakisM.KodounisA.TsagkaropoulosA.KonitsiotisS.ToulasP.PapadimitriouA.PapadimitriouD.TavernarakisA.et al.Natalizumab-related progressive multifocal" exact="leukoencephalopathy" post="in GreeceMult. Scler. Relat. Disord.2014320321010.1016/j.msard.2013.08.00625878008 88.Sanchez-QuintanaA.Breña-AtienzaJ.Marrero-SantosC.Alvarez-AcostaL.Late relapse of progressive"/>
  <result pre="multifocal leukoencephalopathy in GreeceMult. Scler. Relat. Disord.2014320321010.1016/j.msard.2013.08.00625878008 88.Sanchez-QuintanaA.Breña-AtienzaJ.Marrero-SantosC.Alvarez-AcostaL.Late relapse of" exact="progressive multifocal" post="leucoencephalopathy postallogenic transplant in a young patient with CLLBMJ"/>
  <result pre="young patient with CLLBMJ Case Rep.2013201310.1136/bcr-2013-200213 89.SchröderA.LeeD.H.HellwigK.LukasC.LinkerR.A.GoldR.Successful management of natalizumab-associated" exact="progressive multifocal leukoencephalopathy" post="and immune reconstitution syndrome in a patient with multiple"/>
  <result pre="with CLLBMJ Case Rep.2013201310.1136/bcr-2013-200213 89.SchröderA.LeeD.H.HellwigK.LukasC.LinkerR.A.GoldR.Successful management of natalizumab-associated progressive multifocal" exact="leukoencephalopathy" post="and immune reconstitution syndrome in a patient with multiple"/>
  <result pre="89.SchröderA.LeeD.H.HellwigK.LukasC.LinkerR.A.GoldR.Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution" exact="syndrome" post="in a patient with multiple sclerosisArch. Neurol.2010671391139410.1001/archneurol.2010.15720625069 90.McGuireJ.L.FridmanV.WüthrichC.KoralnikI.J.JacobsD.Progressive multifocal"/>
  <result pre="syndrome in a patient with multiple sclerosisArch. Neurol.2010671391139410.1001/archneurol.2010.15720625069 90.McGuireJ.L.FridmanV.WüthrichC.KoralnikI.J.JacobsD.Progressive multifocal" exact="leukoencephalopathy" post="associated with isolated CD8+ T-lymphocyte deficiency mimicking tumefactive MSJ."/>
  <result pre="multiple sclerosisArch. Neurol.2010671391139410.1001/archneurol.2010.15720625069 90.McGuireJ.L.FridmanV.WüthrichC.KoralnikI.J.JacobsD.Progressive multifocal leukoencephalopathy associated with isolated CD8+" exact="T-lymphocyte deficiency" post="mimicking tumefactive MSJ. Neurovirol.20111750050310.1007/s13365-011-0045-221786075 91.PallinM.O’SullivanC.DoddJ.D.McCreeryK.BrettF.FarrellM.O’BrienD.HallW.W.TubridyN.J.KeaneM.P.A case of progressive multifocal"/>
  <result pre="sclerosisArch. Neurol.2010671391139410.1001/archneurol.2010.15720625069 90.McGuireJ.L.FridmanV.WüthrichC.KoralnikI.J.JacobsD.Progressive multifocal leukoencephalopathy associated with isolated CD8+ T-lymphocyte" exact="deficiency" post="mimicking tumefactive MSJ. Neurovirol.20111750050310.1007/s13365-011-0045-221786075 91.PallinM.O’SullivanC.DoddJ.D.McCreeryK.BrettF.FarrellM.O’BrienD.HallW.W.TubridyN.J.KeaneM.P.A case of progressive multifocal"/>
  <result pre="CD8+ T-lymphocyte deficiency mimicking tumefactive MSJ. Neurovirol.20111750050310.1007/s13365-011-0045-221786075 91.PallinM.O’SullivanC.DoddJ.D.McCreeryK.BrettF.FarrellM.O’BrienD.HallW.W.TubridyN.J.KeaneM.P.A case of" exact="progressive multifocal leukoencephalopathy" post="in a patient with sarcoidosisQJM20121051011101610.1093/qjmed/hcr15421893584 92.ChristakisP.G.OkinD.HuttnerA.J.BaehringJ.M.Progressive multifocal leukoencephalopathy in"/>
  <result pre="deficiency mimicking tumefactive MSJ. Neurovirol.20111750050310.1007/s13365-011-0045-221786075 91.PallinM.O’SullivanC.DoddJ.D.McCreeryK.BrettF.FarrellM.O’BrienD.HallW.W.TubridyN.J.KeaneM.P.A case of progressive multifocal" exact="leukoencephalopathy" post="in a patient with sarcoidosisQJM20121051011101610.1093/qjmed/hcr15421893584 92.ChristakisP.G.OkinD.HuttnerA.J.BaehringJ.M.Progressive multifocal leukoencephalopathy in"/>
  <result pre="progressive multifocal leukoencephalopathy in a patient with sarcoidosisQJM20121051011101610.1093/qjmed/hcr15421893584 92.ChristakisP.G.OkinD.HuttnerA.J.BaehringJ.M.Progressive multifocal" exact="leukoencephalopathy" post="in an immunocompetent patientJ. Neurol. Sci.201332610711010.1016/j.jns.2013.01.01023375959 93.LindåH.von HeijneA.Presymptomatic diagnosis"/>
  <result pre="with MRI and adequate treatment ameliorate the outcome after natalizumab-associated" exact="progressive multifocal" post="leukoencephalopathyFront. Neurol.201341110.3389/fneur.2013.0001123423248 94.EpperlaN.Medina-FloresR.MazzaJ.J.YaleS.H.Mirtazapine and mefloquine therapy for non-AIDS-related progressive"/>
  <result pre="progressive multifocal leukoencephalopathyFront. Neurol.201341110.3389/fneur.2013.0001123423248 94.EpperlaN.Medina-FloresR.MazzaJ.J.YaleS.H.Mirtazapine and mefloquine therapy for non-AIDS-related" exact="progressive multifocal" post="leukoencephalopathyWMJ201411324224525745699 95.KurmannR.WeisstannerC.KardasP.HirschH.H.WiestR.LämmleB.FurrerH.Du PasquierR.BassettiC.L.SturzeneggerM.et al.Progressive multifocal leukoencephalopathy in common variable"/>
  <result pre="therapy for non-AIDS-related progressive multifocal leukoencephalopathyWMJ201411324224525745699 95.KurmannR.WeisstannerC.KardasP.HirschH.H.WiestR.LämmleB.FurrerH.Du PasquierR.BassettiC.L.SturzeneggerM.et al.Progressive multifocal" exact="leukoencephalopathy" post="in common variable immunodeficiency: Mitigated course under mirtazapine and"/>
  <result pre="immunodeficiency: Mitigated course under mirtazapine and mefloquineJ. Neurovirol.20152169470110.1007/s13365-015-0340-425916731 96.BalakD.M.W.HajdarbegovicE.BramerW.M.NeumannH.A.M.ThioH.B.Progressive multifocal" exact="leukoencephalopathy" post="associated with fumaric acid esters treatment in psoriasis patientsJ."/>
  <result pre="96.BalakD.M.W.HajdarbegovicE.BramerW.M.NeumannH.A.M.ThioH.B.Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in" exact="psoriasis" post="patientsJ. Eur. Acad. Dermatol. Venereol.2017311475148210.1111/jdv.1423628322482 97.YoshidaH.OhshimaK.TodaJ.KusakabeS.MasaieH.YagiT.IshikawaJ.Significant improvement following combination"/>
  <result pre="combination treatment with mefloquine and mirtazapine in a patient with" exact="progressive multifocal leukoencephalopathy" post="after allogeneic peripheral blood stem cell transplantationInt. J. Hematol.201499959910.1007/s12185-013-1471-024264833"/>
  <result pre="with mefloquine and mirtazapine in a patient with progressive multifocal" exact="leukoencephalopathy" post="after allogeneic peripheral blood stem cell transplantationInt. J. Hematol.201499959910.1007/s12185-013-1471-024264833"/>
  <result pre="mirtazapine in a patient with progressive multifocal leukoencephalopathy after allogeneic" exact="peripheral" post="blood stem cell transplantationInt. J. Hematol.201499959910.1007/s12185-013-1471-024264833 98.CalicZ.Cappelen-SmithC.HodgkinsonS.J.McDougallA.CuganesanR.BrewB.J.Treatment of progressive"/>
  <result pre="allogeneic peripheral blood stem cell transplantationInt. J. Hematol.201499959910.1007/s12185-013-1471-024264833 98.CalicZ.Cappelen-SmithC.HodgkinsonS.J.McDougallA.CuganesanR.BrewB.J.Treatment of" exact="progressive multifocal" post="leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a"/>
  <result pre="transplantationInt. J. Hematol.201499959910.1007/s12185-013-1471-024264833 98.CalicZ.Cappelen-SmithC.HodgkinsonS.J.McDougallA.CuganesanR.BrewB.J.Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory" exact="syndrome" post="with intravenous immunoglobulin in a patient with multiple sclerosis"/>
  <result pre="reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with" exact="multiple sclerosis" post="treated with fingolimod after discontinuation of natalizumabJ. Clin. Neurosci.20152259860010.1016/j.jocn.2014.08.01625523125"/>
  <result pre="with fingolimod after discontinuation of natalizumabJ. Clin. Neurosci.20152259860010.1016/j.jocn.2014.08.01625523125 99.SilverioK.A.PatelS.A.Progressive Multifocal" exact="Leukoencephalopathy" post="with Negative JC Virus PCR following Treatment of Follicular"/>
  <result pre="Multifocal Leukoencephalopathy with Negative JC Virus PCR following Treatment of" exact="Follicular" post="Lymphoma: Implications for Biologics in the Era of Targeted"/>
  <result pre="Follicular Lymphoma: Implications for Biologics in the Era of Targeted" exact="Cancer" post="TherapyCase Rep. Oncol. Med.2015201553452910.1155/2015/53452926788389 100.Fabis-PedriniM.J.XuW.BurtonJ.CarrollW.M.KermodeA.G.Asymptomatic progressive multifocal leukoencephalopathy during"/>
  <result pre="the Era of Targeted Cancer TherapyCase Rep. Oncol. Med.2015201553452910.1155/2015/53452926788389 100.Fabis-PedriniM.J.XuW.BurtonJ.CarrollW.M.KermodeA.G.Asymptomatic" exact="progressive multifocal leukoencephalopathy" post="during natalizumab therapy with treatmentJ. Clin. Neurosci.20162514514710.1016/j.jocn.2015.08.02726541323 101.IkedaJ.MatsushimaA.IshiiW.GotoT.TakahashiK.NakamichiK.SaijoM.SekijimaY.IkedaS.I.Brain Biopsy"/>
  <result pre="of Targeted Cancer TherapyCase Rep. Oncol. Med.2015201553452910.1155/2015/53452926788389 100.Fabis-PedriniM.J.XuW.BurtonJ.CarrollW.M.KermodeA.G.Asymptomatic progressive multifocal" exact="leukoencephalopathy" post="during natalizumab therapy with treatmentJ. Clin. Neurosci.20162514514710.1016/j.jocn.2015.08.02726541323 101.IkedaJ.MatsushimaA.IshiiW.GotoT.TakahashiK.NakamichiK.SaijoM.SekijimaY.IkedaS.I.Brain Biopsy"/>
  <result pre="for JC Virus in Cerebrospinal Fluid for the Diagnosis of" exact="Progressive" post="Multifocal LeukoencephalopathyIntern. Med.2017561231123410.2169/internalmedicine.56.768928502942 102.NambirajanA.SuriV.KatariaV.SharmaM.C.GoyalV.Progressive multifocal leukoencephalopathy in a 44-year"/>
  <result pre="for the Diagnosis of Progressive Multifocal LeukoencephalopathyIntern. Med.2017561231123410.2169/internalmedicine.56.768928502942 102.NambirajanA.SuriV.KatariaV.SharmaM.C.GoyalV.Progressive multifocal" exact="leukoencephalopathy" post="in a 44-year old male with idiopathic CD4+ T-lymphocytopenia"/>
  <result pre="treated with mirtazapine and mefloquineNeurol. India2017651061106410.4103/neuroindia.NI_535_1628879898 103.IshikawaY.KasuyaT.IshikawaJ.FujiwaraM.KitaY.A case of developing" exact="progressive multifocal leukoencephalopathy" post="while using rituximab and mycophenolate mofetil in refractory systemic"/>
  <result pre="mirtazapine and mefloquineNeurol. India2017651061106410.4103/neuroindia.NI_535_1628879898 103.IshikawaY.KasuyaT.IshikawaJ.FujiwaraM.KitaY.A case of developing progressive multifocal" exact="leukoencephalopathy" post="while using rituximab and mycophenolate mofetil in refractory systemic"/>
  <result pre="multifocal leukoencephalopathy while using rituximab and mycophenolate mofetil in refractory" exact="systemic" post="lupus erythematosusTher. Clin. Risk Manag.2018141149115310.2147/TCRM.S16710929983569 104.IkedaK.M.DasS.StrongM.MirsattariS.M.LeungA.StevenD.HammondR.Diagnosis of InclusionCan. J."/>
  <result pre="leukoencephalopathy while using rituximab and mycophenolate mofetil in refractory systemic" exact="lupus" post="erythematosusTher. Clin. Risk Manag.2018141149115310.2147/TCRM.S16710929983569 104.IkedaK.M.DasS.StrongM.MirsattariS.M.LeungA.StevenD.HammondR.Diagnosis of InclusionCan. J. Neurol."/>
  <result pre="Clin. Risk Manag.2018141149115310.2147/TCRM.S16710929983569 104.IkedaK.M.DasS.StrongM.MirsattariS.M.LeungA.StevenD.HammondR.Diagnosis of InclusionCan. J. Neurol. Sci.20154213814310.1017/cjn.2015.227482558 105.NishigoriR.WarabiY.Shishido-HaraY.NakamichiK.NakataY.KomoriT.IsozakiE.Inflammatory" exact="Cerebellar" post="PML with a CD4/CD8 ratio of 2.9 Showed a"/>
  <result pre="Patient with Rheumatoid Arthritis: A Case ReportIntern. Med.201910.2169/internalmedicine.3038-19 106.AlTahanA.M.BergerT.AlOrainyI.A.AlTahanH.Progressive Multifocal" exact="Leukoencephalopathy" post="in the Absence of Typical Radiological Changes: Can We"/>
  <result pre="Arthritis: A Case ReportIntern. Med.201910.2169/internalmedicine.3038-19 106.AlTahanA.M.BergerT.AlOrainyI.A.AlTahanH.Progressive Multifocal Leukoencephalopathy in the" exact="Absence of" post="Typical Radiological Changes: Can We Make a Diagnosis?Am. J."/>
  <result pre="We Make a Diagnosis?Am. J. Case Rep.20192010110510.12659/AJCR.91152130674865 107.HarelA.HorngS.GustafsonT.RamineniA.FarberR.S.FabianM.Successful treatment of" exact="progressive multifocal leukoencephalopathy" post="with recombinant interleukin-7 and maraviroc in a patient with"/>
  <result pre="a Diagnosis?Am. J. Case Rep.20192010110510.12659/AJCR.91152130674865 107.HarelA.HorngS.GustafsonT.RamineniA.FarberR.S.FabianM.Successful treatment of progressive multifocal" exact="leukoencephalopathy" post="with recombinant interleukin-7 and maraviroc in a patient with"/>
  <result pre="maraviroc in a patient with idiopathic CD4 lymphocytopeniaJ. Neurovirol.20182465265510.1007/s13365-018-0657-x29987583 108.ZhangY.WrightC.FloresA.Asymptomatic" exact="progressive multifocal" post="leukoencephalopathy: A case report and review of the literatureJ."/>
  <result pre="109.Soleimani-MeigooniD.N.SchwetyeK.E.AngelesM.R.RyschkewitschC.F.MajorE.O.DangX.KoralnikI.J.SchmidtR.E.CliffordD.B.KuhlmannF.M.et al.JC virus granule cell neuronopathy in the setting of" exact="chronic" post="lymphopenia treated with recombinant interleukin-7J. Neurovirol.20172314114610.1007/s13365-016-0465-027421731 110.BerntssonS.G.KatsarogiannisE.LourençoF.Moraes-FontesM.F.Progressive Multifocal Leukoencephalopathy"/>
  <result pre="al.JC virus granule cell neuronopathy in the setting of chronic" exact="lymphopenia" post="treated with recombinant interleukin-7J. Neurovirol.20172314114610.1007/s13365-016-0465-027421731 110.BerntssonS.G.KatsarogiannisE.LourençoF.Moraes-FontesM.F.Progressive Multifocal Leukoencephalopathy and"/>
  <result pre="of chronic lymphopenia treated with recombinant interleukin-7J. Neurovirol.20172314114610.1007/s13365-016-0465-027421731 110.BerntssonS.G.KatsarogiannisE.LourençoF.Moraes-FontesM.F.Progressive Multifocal" exact="Leukoencephalopathy" post="and Systemic Lupus Erythematosus: Focus on EtiologyCase Rep. Neurol.20168596510.1159/00044487427065427"/>
  <result pre="lymphopenia treated with recombinant interleukin-7J. Neurovirol.20172314114610.1007/s13365-016-0465-027421731 110.BerntssonS.G.KatsarogiannisE.LourençoF.Moraes-FontesM.F.Progressive Multifocal Leukoencephalopathy and" exact="Systemic" post="Lupus Erythematosus: Focus on EtiologyCase Rep. Neurol.20168596510.1159/00044487427065427 111.Di PauliF.BergerT.WalderA.MaierH.RhombergP.UprimnyC.SteurerM.StockhammerG.Progressive"/>
  <result pre="treated with recombinant interleukin-7J. Neurovirol.20172314114610.1007/s13365-016-0465-027421731 110.BerntssonS.G.KatsarogiannisE.LourençoF.Moraes-FontesM.F.Progressive Multifocal Leukoencephalopathy and Systemic" exact="Lupus" post="Erythematosus: Focus on EtiologyCase Rep. Neurol.20168596510.1159/00044487427065427 111.Di PauliF.BergerT.WalderA.MaierH.RhombergP.UprimnyC.SteurerM.StockhammerG.Progressive multifocal"/>
  <result pre="Lupus Erythematosus: Focus on EtiologyCase Rep. Neurol.20168596510.1159/00044487427065427 111.Di PauliF.BergerT.WalderA.MaierH.RhombergP.UprimnyC.SteurerM.StockhammerG.Progressive multifocal" exact="leukoencephalopathy" post="complicating untreated chronic lymphatic leukemia: Case report and review"/>
  <result pre="on EtiologyCase Rep. Neurol.20168596510.1159/00044487427065427 111.Di PauliF.BergerT.WalderA.MaierH.RhombergP.UprimnyC.SteurerM.StockhammerG.Progressive multifocal leukoencephalopathy complicating untreated" exact="chronic" post="lymphatic leukemia: Case report and review of the literatureJ."/>
  <result pre="report and review of the literatureJ. Clin. Virol.20146042442710.1016/j.jcv.2014.05.00724929753 112.UenoT.SatoN.KonT.HagaR.NunomuraJ.I.NakamichiK.SaijoM.TomiyamaM.Progressive multifocal" exact="leukoencephalopathy" post="associated with thymoma with immunodeficiency: A case report and"/>
  <result pre="of the literatureJ. Clin. Virol.20146042442710.1016/j.jcv.2014.05.00724929753 112.UenoT.SatoN.KonT.HagaR.NunomuraJ.I.NakamichiK.SaijoM.TomiyamaM.Progressive multifocal leukoencephalopathy associated with" exact="thymoma" post="with immunodeficiency: A case report and literature reviewBMC Neurol.2018183710.1186/s12883-018-1041-429631544"/>
  <result pre="A case report and literature reviewBMC Neurol.2018183710.1186/s12883-018-1041-429631544 113.IkegawaS.FujiiN.TadokoroK.SatoK.IwamotoM.MatsudaM.InomataT.SugiuraH.AsanoT.YoshidaS.et al.Progressive multifocal" exact="leukoencephalopathy" post="after T-cell replete HLA-haploidentical transplantation with post-transplantation cyclophosphamide graft-versus-host"/>
  <result pre="leukoencephalopathy after T-cell replete HLA-haploidentical transplantation with post-transplantation cyclophosphamide graft-versus-host" exact="disease" post="prophylaxisTranspl. Infect. Dis.201820e1285010.1111/tid.1285029359846 114.LutzM.SchulzeA.B.RebberE.WiebeS.ZoubiT.GrauerO.M.KeßlerT.KerkhoffA.LenzG.BerdelW.E.Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy"/>
  <result pre="with post-transplantation cyclophosphamide graft-versus-host disease prophylaxisTranspl. Infect. Dis.201820e1285010.1111/tid.1285029359846 114.LutzM.SchulzeA.B.RebberE.WiebeS.ZoubiT.GrauerO.M.KeßlerT.KerkhoffA.LenzG.BerdelW.E.Progressive Multifocal" exact="Leukoencephalopathy" post="after Ibrutinib Therapy for Chronic Lymphocytic LeukemiaCancer Res. Treat.20174954855210.4143/crt.2016.11027456945"/>
  <result pre="prophylaxisTranspl. Infect. Dis.201820e1285010.1111/tid.1285029359846 114.LutzM.SchulzeA.B.RebberE.WiebeS.ZoubiT.GrauerO.M.KeßlerT.KerkhoffA.LenzG.BerdelW.E.Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for" exact="Chronic" post="Lymphocytic LeukemiaCancer Res. Treat.20174954855210.4143/crt.2016.11027456945 115.WüthrichC.PopescuB.F.GheuensS.MarviM.ZimanR.DenqS.P.ThamM.NortonE.ParisiJ.E.DangX.et al.Natalizumab-associated progressive multifocal leukoencephalopathy"/>
  <result pre="Ibrutinib Therapy for Chronic Lymphocytic LeukemiaCancer Res. Treat.20174954855210.4143/crt.2016.11027456945 115.WüthrichC.PopescuB.F.GheuensS.MarviM.ZimanR.DenqS.P.ThamM.NortonE.ParisiJ.E.DangX.et al.Natalizumab-associated" exact="progressive multifocal leukoencephalopathy" post="in a patient with multiple sclerosis: A postmortem studyJ."/>
  <result pre="for Chronic Lymphocytic LeukemiaCancer Res. Treat.20174954855210.4143/crt.2016.11027456945 115.WüthrichC.PopescuB.F.GheuensS.MarviM.ZimanR.DenqS.P.ThamM.NortonE.ParisiJ.E.DangX.et al.Natalizumab-associated progressive multifocal" exact="leukoencephalopathy" post="in a patient with multiple sclerosis: A postmortem studyJ."/>
  <result pre="multiple sclerosis: A postmortem studyJ. Neuropathol. Exp. Neurol.2013721043105110.1097/NEN.000000000000000524128680 116.KalischA.WilhelmM.ErbguthF.BirkmannJ.Progressive multifocal" exact="leukoencephalopathy" post="in patients with a hematological malignancy: Review of therapeutic"/>
  <result pre="with a hematological malignancy: Review of therapeutic optionsChemotherapy201460475310.1159/00036807225376181 117.MeisterS.BeneckeR.KönigF.B.GroßmannA.ZettlU.K.WinkelmannA.Progressive multifocal" exact="leukoencephalopathy" post="in a patient with pre-clinical primary biliary cirrhosisClin. Neurol."/>
  <result pre="therapeutic optionsChemotherapy201460475310.1159/00036807225376181 117.MeisterS.BeneckeR.KönigF.B.GroßmannA.ZettlU.K.WinkelmannA.Progressive multifocal leukoencephalopathy in a patient with pre-clinical" exact="primary" post="biliary cirrhosisClin. Neurol. Neurosurg.2014123454910.1016/j.clineuro.2014.04.03225012010 118.MotteJ.KneiphofJ.Straßburger-KrogiasK.KlasingA.AdamsO.HaghikiaA.GoldR.Detection of JC virus archetype"/>
  <result pre="cerebrospinal fluid in a MS patient with dimethylfumarate treatment without" exact="lymphopenia" post="or signs of PMLJ. Neurol.20182651880188210.1007/s00415-018-8931-729948248 119.ZuckerB.E.StacpooleS.R.L.Progressive multifocal leukoencephalopathy in"/>
  <result pre="treatment without lymphopenia or signs of PMLJ. Neurol.20182651880188210.1007/s00415-018-8931-729948248 119.ZuckerB.E.StacpooleS.R.L.Progressive multifocal" exact="leukoencephalopathy" post="in the absence of immunosuppressionJ. Neurovirol.20182411912210.1007/s13365-017-0592-229139004 120.SanjoN.KinaS.Shishido-HaraY.NoseY.IshibashiS.FukudaT.MaeharaT.EishiY.MizusawaH.YokotaT.Progressive Multifocal Leukoencephalopathy"/>
  <result pre="or signs of PMLJ. Neurol.20182651880188210.1007/s00415-018-8931-729948248 119.ZuckerB.E.StacpooleS.R.L.Progressive multifocal leukoencephalopathy in the" exact="absence of" post="immunosuppressionJ. Neurovirol.20182411912210.1007/s13365-017-0592-229139004 120.SanjoN.KinaS.Shishido-HaraY.NoseY.IshibashiS.FukudaT.MaeharaT.EishiY.MizusawaH.YokotaT.Progressive Multifocal Leukoencephalopathy with Balanced CD4/CD8 T-Cell"/>
  <result pre="multifocal leukoencephalopathy in the absence of immunosuppressionJ. Neurovirol.20182411912210.1007/s13365-017-0592-229139004 120.SanjoN.KinaS.Shishido-HaraY.NoseY.IshibashiS.FukudaT.MaeharaT.EishiY.MizusawaH.YokotaT.Progressive Multifocal" exact="Leukoencephalopathy" post="with Balanced CD4/CD8 T-Cell Infiltration and Good Response to"/>
  <result pre="absence of immunosuppressionJ. Neurovirol.20182411912210.1007/s13365-017-0592-229139004 120.SanjoN.KinaS.Shishido-HaraY.NoseY.IshibashiS.FukudaT.MaeharaT.EishiY.MizusawaH.YokotaT.Progressive Multifocal Leukoencephalopathy with Balanced CD4/CD8" exact="T-Cell" post="Infiltration and Good Response to Mefloquine TreatmentIntern. Med.2016551631163510.2169/internalmedicine.55.605127301518 121.HervásJ.V.Presas-RodríguezS.Crespo-CuevasA.M.CanentoT.Lozano-SánchezM.Massuet-VilamajóA.Ramo-TelloC.Progressive"/>
  <result pre="Infiltration and Good Response to Mefloquine TreatmentIntern. Med.2016551631163510.2169/internalmedicine.55.605127301518 121.HervásJ.V.Presas-RodríguezS.Crespo-CuevasA.M.CanentoT.Lozano-SánchezM.Massuet-VilamajóA.Ramo-TelloC.Progressive multifocal" exact="leukoencephalopathy" post="associated to natalizumab extended dosing regimenNeurodegener. Dis. Manag.2015539940210.2217/nmt.15.4226517599 122.MikitaK.MaedaT.FujikuraY.KozakiY.HaraY.KanohS.KishidaS.SaijoM.NakamichiK.KawanaA.Does"/>
  <result pre="improve the prognosis of AIDS-related PML?Clin. Neurol. Neurosurg.20131151853185410.1016/j.clineuro.2013.01.01323481900 123.YoungB.E.YeoT.R.LimH.T.VongK.Y.TanK.LyeD.C.LeeC.C.Progressive Multifocal" exact="Leukoencephalopathy" post="with Immune Reconstitution Inflammatory Syndrome (PML-IRIS): Two case reports"/>
  <result pre="AIDS-related PML?Clin. Neurol. Neurosurg.20131151853185410.1016/j.clineuro.2013.01.01323481900 123.YoungB.E.YeoT.R.LimH.T.VongK.Y.TanK.LyeD.C.LeeC.C.Progressive Multifocal Leukoencephalopathy with Immune Reconstitution" exact="Inflammatory" post="Syndrome (PML-IRIS): Two case reports of successful treatment with"/>
  <result pre="PML?Clin. Neurol. Neurosurg.20131151853185410.1016/j.clineuro.2013.01.01323481900 123.YoungB.E.YeoT.R.LimH.T.VongK.Y.TanK.LyeD.C.LeeC.C.Progressive Multifocal Leukoencephalopathy with Immune Reconstitution Inflammatory" exact="Syndrome" post="(PML-IRIS): Two case reports of successful treatment with mefloquine"/>
  <result pre="review of the literatureAnn. Acad. Med. Singap.20124162062423303123 124.AdachiE.KoibuchiT.ImaiK.KikuchiT.KogaM.NakamuraH.MiuraT.IwamotoA.FujiiT.Favourable outcome of" exact="progressive multifocal leukoencephalopathy" post="with mefloquine treatment in combination with antiretroviral therapy in"/>
  <result pre="the literatureAnn. Acad. Med. Singap.20124162062423303123 124.AdachiE.KoibuchiT.ImaiK.KikuchiT.KogaM.NakamuraH.MiuraT.IwamotoA.FujiiT.Favourable outcome of progressive multifocal" exact="leukoencephalopathy" post="with mefloquine treatment in combination with antiretroviral therapy in"/>
  <result pre="antiretroviral therapy in an HIV-infected patientInt. J. STD AIDS20122360360510.1258/ijsa.2012.01130522930304 125.NaitoK.UenoH.SekineM.KanemitsuM.OhshitaT.NakamuraT.YamawakiT.MatsumotoM.Akinetic" exact="mutism" post="caused by HIV-associated progressive multifocal leukoencephalopathy was successfully treated"/>
  <result pre="HIV-infected patientInt. J. STD AIDS20122360360510.1258/ijsa.2012.01130522930304 125.NaitoK.UenoH.SekineM.KanemitsuM.OhshitaT.NakamuraT.YamawakiT.MatsumotoM.Akinetic mutism caused by HIV-associated" exact="progressive multifocal leukoencephalopathy" post="was successfully treated with mefloquine: A serial multimodal MRI"/>
  <result pre="J. STD AIDS20122360360510.1258/ijsa.2012.01130522930304 125.NaitoK.UenoH.SekineM.KanemitsuM.OhshitaT.NakamuraT.YamawakiT.MatsumotoM.Akinetic mutism caused by HIV-associated progressive multifocal" exact="leukoencephalopathy" post="was successfully treated with mefloquine: A serial multimodal MRI"/>
  <result pre="mefloquine: A serial multimodal MRI StudyIntern. Med.20125120520910.2169/internalmedicine.51.625322246492 126.KawakamiT.SakaiK.MimuraY.SenooY.HirabayashiY.NakazawaH.KoshiharaH.OguchiK.TakeiY.OharaS.et al.Development of" exact="primary" post="central nervous system lymphoma associated with human immunodeficiency virus"/>
  <result pre="A serial multimodal MRI StudyIntern. Med.20125120520910.2169/internalmedicine.51.625322246492 126.KawakamiT.SakaiK.MimuraY.SenooY.HirabayashiY.NakazawaH.KoshiharaH.OguchiK.TakeiY.OharaS.et al.Development of primary" exact="central nervous system lymphoma" post="associated with human immunodeficiency virus and JC virus infectionJ."/>
  <result pre="MRI StudyIntern. Med.20125120520910.2169/internalmedicine.51.625322246492 126.KawakamiT.SakaiK.MimuraY.SenooY.HirabayashiY.NakazawaH.KoshiharaH.OguchiK.TakeiY.OharaS.et al.Development of primary central nervous system" exact="lymphoma" post="associated with human immunodeficiency virus and JC virus infectionJ."/>
  <result pre="al.Development of primary central nervous system lymphoma associated with human" exact="immunodeficiency" post="virus and JC virus infectionJ. Clin. Exp. Hematop.20145421121710.3960/jslrt.54.21125501112 127.MoensterR.P.JettR.A.Mirtazapine"/>
  <result pre="virus infectionJ. Clin. Exp. Hematop.20145421121710.3960/jslrt.54.21125501112 127.MoensterR.P.JettR.A.Mirtazapine and mefloquine therapy for" exact="progressive multifocal leukoencephalopathy" post="in a patient infected with human immunodeficiency virusAm. J."/>
  <result pre="Clin. Exp. Hematop.20145421121710.3960/jslrt.54.21125501112 127.MoensterR.P.JettR.A.Mirtazapine and mefloquine therapy for progressive multifocal" exact="leukoencephalopathy" post="in a patient infected with human immunodeficiency virusAm. J."/>
  <result pre="for progressive multifocal leukoencephalopathy in a patient infected with human" exact="immunodeficiency" post="virusAm. J. Health Syst. Pharm.20126949649810.2146/ajhp11039222382480 128.IannettaM.BellizziA.Lo MenzoS.AnzivinoE.D’AbramoA.OlivaA.D’AgostinoC.d’EttorreG.PietropaoloV.VulloV.et al.HIV-associated progressive"/>
  <result pre="human immunodeficiency virusAm. J. Health Syst. Pharm.20126949649810.2146/ajhp11039222382480 128.IannettaM.BellizziA.Lo MenzoS.AnzivinoE.D’AbramoA.OlivaA.D’AgostinoC.d’EttorreG.PietropaoloV.VulloV.et al.HIV-associated" exact="progressive multifocal" post="leukoencephalopathy: Longitudinal study of JC virus non-coding control region"/>
  <result pre="and host immunityJ. Neurovirol.20131927427910.1007/s13365-013-0167-923715894 129.CliffordD.B.NathA.CinqueP.BrewB.J.ZivadinovR.GorelikL.ZhaoZ.DudaP.A study of mefloquine treatment for" exact="progressive multifocal" post="leukoencephalopathy: Results and exploration of predictors of PML outcomesJ."/>
  <result pre="Host Microbe20162025927010.1016/j.chom.2016.07.00427476412 131.BalasubramanianA.TeramotoT.KulkarniA.A.BhattacharjeeA.K.PadmanabhanR.Antiviral activities of selected antimalarials against dengue virus" exact="type 2" post="and Zika virusAntivir. Res201713714115010.1016/j.antiviral.2016.11.01527889529 132.SunW.HeS.Martínez-RomeroC.KouznetsovaJ.TawaG.XuM.ShinnP.FisherE.LongY.MotabarO.et al.Synergistic drug combination effectively"/>
  <result pre="Res. Perspect.2017510.1002/prp2.32828805982 134.MazzonM.Ortega-PrietoA.M.ImrieD.LuftC.HessL.CziesoS.GroveJ.SkeltonJ.K.FarleighL.BugertJ.J.et al.Identification of Broad-Spectrum Antiviral Compounds by Targeting" exact="Viral" post="EntryViruses20191117610.3390/v1102017630791609 135.Al-BariM.A.Chloroquine analogues in drug discovery: New directions of"/>
  <result pre="directions of uses, mechanisms of actions and toxic manifestations from" exact="malaria" post="to multifarious diseasesJ. Antimicrob. Chemother.2015701608162110.1093/jac/dkv01825693996 136.ShimizuY.YamamotoS.HommaM.IshidaN.Effect of chloroquine on"/>
  <result pre="in vero cellsJ. Med. Virol.20108281782410.1002/jmv.2166320336760 139.SourisseauM.SchilteC.CasartelliN.TrouilletC.Guivel-BenhassineF.RudnickaD.Sol-FoulonN.Le RouxK.PrevostM.C.FsihiH.et al.Characterization of reemerging" exact="chikungunya" post="virusPLoS Pathog.20073e8910.1371/journal.ppat.003008917604450 140.HanY.MesplèdeT.XuH.QuanY.WainbergM.A.The antimalarial drug amodiaquine possesses anti-ZIKA virus"/>
  <result pre="Virol.20189079680210.1002/jmv.2503129315671 141.DelvecchioR.HigaL.M.PezzutoP.ValadãoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.AliotaM.T.et al.Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus" exact="Infection" post="in Different Cell ModelsViruses2016832210.3390/v8120322 142.DowallS.D.BosworthA.WatsonR.BewleyK.TaylorI.RaynerE.HunterL.PearsonG.EasterbrookL.PitmanJ.et al.Chloroquine inhibited Ebola virus"/>
  <result pre="Ebola virus replication in vitro but failed to protect against" exact="infection" post="and disease in the in vivo guinea pig modelJ."/>
  <result pre="replication in vitro but failed to protect against infection and" exact="disease" post="in the in vivo guinea pig modelJ. Gen. Virol.2015963484349210.1099/jgv.0.00030926459826"/>
  <result pre="ONE20138e6057910.1371/journal.pone.006057923577127 144.AkpovwaH.Chloroquine could be used for the treatment of filoviral" exact="infections" post="and other viral infections that emerge or emerged from"/>
  <result pre="be used for the treatment of filoviral infections and other" exact="viral" post="infections that emerge or emerged from viruses requiring an"/>
  <result pre="used for the treatment of filoviral infections and other viral" exact="infections" post="that emerge or emerged from viruses requiring an acidic"/>
  <result pre="infectivityCell Biochem. Funct.20163419119610.1002/cbf.318227001679 145.VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS" exact="coronavirus infection" post="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 146.KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of chloroquine against"/>
  <result pre="Biochem. Funct.20163419119610.1002/cbf.318227001679 145.VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 146.KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of chloroquine against"/>
  <result pre="J.200526910.1186/1743-422X-2-6916115318 146.KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.MaesP.Antiviral activity of chloroquine against human coronavirus OC43" exact="infection" post="in newborn miceAntimicrob. Agents Chemother.2009533416342110.1128/AAC.01509-0819506054 147.KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition"/>
  <result pre="newborn miceAntimicrob. Agents Chemother.2009533416342110.1128/AAC.01509-0819506054 147.KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition of severe" exact="acute" post="respiratory syndrome coronavirus by chloroquineBiochem. Biophys. Res. Commun.200432326426810.1016/j.bbrc.2004.08.08515351731 148.BlanchardE.BelouzardS.GoueslainL.WakitaT.DubuissonJ.WychowskiC.RouilléY.Hepatitis"/>
  <result pre="miceAntimicrob. Agents Chemother.2009533416342110.1128/AAC.01509-0819506054 147.KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition of severe acute" exact="respiratory" post="syndrome coronavirus by chloroquineBiochem. Biophys. Res. Commun.200432326426810.1016/j.bbrc.2004.08.08515351731 148.BlanchardE.BelouzardS.GoueslainL.WakitaT.DubuissonJ.WychowskiC.RouilléY.Hepatitis C"/>
  <result pre="Agents Chemother.2009533416342110.1128/AAC.01509-0819506054 147.KeyaertsE.VijgenL.MaesP.NeytsJ.Van RanstM.In vitro inhibition of severe acute respiratory" exact="syndrome" post="coronavirus by chloroquineBiochem. Biophys. Res. Commun.200432326426810.1016/j.bbrc.2004.08.08515351731 148.BlanchardE.BelouzardS.GoueslainL.WakitaT.DubuissonJ.WychowskiC.RouilléY.Hepatitis C virus"/>
  <result pre="virus entry depends on clathrin-mediated endocytosisJ. Virol.2006806964697210.1128/JVI.00024-0616809302 149.MizuiT.YamashinaS.TanidaI.TakeiY.UenoT.SakamotoN.IkejimaK.KitamuraT.EnomotoN.SakaiT.et al.Inhibition of" exact="hepatitis" post="C virus replication by chloroquine targeting virus-associated autophagyJ. Gastroenterol.20104519520310.1007/s00535-009-0132-919760134"/>
  <result pre="analogs as a promising strategy for the treatment of emerging" exact="viral" post="diseasesPharmacol. Res. Perspect.20175e0029310.1002/prp2.29328596841 151.TsaiW.P.NaraP.L.KungH.F.OroszlanS.Inhibition of human immunodeficiency virus infectivity"/>
  <result pre="treatment of emerging viral diseasesPharmacol. Res. Perspect.20175e0029310.1002/prp2.29328596841 151.TsaiW.P.NaraP.L.KungH.F.OroszlanS.Inhibition of human" exact="immunodeficiency" post="virus infectivity by chloroquineAIDS Res. Hum. Retrovir.1990648148910.1089/aid.1990.6.4811692728 152.SperberK.KalbT.H.StecherV.J.BanerjeeR.MayerL.Inhibition of"/>
  <result pre="virus infectivity by chloroquineAIDS Res. Hum. Retrovir.1990648148910.1089/aid.1990.6.4811692728 152.SperberK.KalbT.H.StecherV.J.BanerjeeR.MayerL.Inhibition of human" exact="immunodeficiency" post="virus type 1 replication by hydroxychloroquine in T cells"/>
  <result pre="by chloroquineAIDS Res. Hum. Retrovir.1990648148910.1089/aid.1990.6.4811692728 152.SperberK.KalbT.H.StecherV.J.BanerjeeR.MayerL.Inhibition of human immunodeficiency virus" exact="type 1" post="replication by hydroxychloroquine in T cells and monocytesAIDS Res."/>
  <result pre="patientsJ. Clin. Virol.20012013714010.1016/S1386-6532(00)00140-211166662 156.SavarinoA.LuciaM.B.RastrelliE.RutellaS.GolottaC.MorraE.TamburriniE.PernoC.F.BoelaertJ.R.SperberK.et al.Anti-HIV effects of chloroquine: Inhibition of" exact="viral" post="particle glycosylation and synergism with protease inhibitorsJ. Acquir. Immune."/>
  <result pre="Mouth DiseaseAntivir. Res.201814914314910.1016/j.antiviral.2017.11.01729175128 162.BoonyasuppayakornS.ReichertE.D.ManzanoM.NagarajanK.PadmanabhanR.Amodiaquine, an antimalarial drug, inhibits dengue virus" exact="type 2" post="replication and infectivityAntivir. Res.201410612513410.1016/j.antiviral.2014.03.01424680954 163.BabaM.ToyamaM.SakakibaraN.OkamotoM.ArimaN.SaijoM.Establishment of an antiviral assay"/>
  <result pre="an antiviral assay system and identification of severe fever with" exact="thrombocytopenia" post="syndrome virus inhibitorsAntivir. Chem. Chemother.201725838910.1177/204020661774030329096526 164.BurdickJ.R.DurandD.P.Primaquine diphosphate: Inhibition of"/>
  <result pre="antiviral assay system and identification of severe fever with thrombocytopenia" exact="syndrome" post="virus inhibitorsAntivir. Chem. Chemother.201725838910.1177/204020661774030329096526 164.BurdickJ.R.DurandD.P.Primaquine diphosphate: Inhibition of Newcastle"/>
  <result pre="thrombocytopenia syndrome virus inhibitorsAntivir. Chem. Chemother.201725838910.1177/204020661774030329096526 164.BurdickJ.R.DurandD.P.Primaquine diphosphate: Inhibition of" exact="Newcastle disease" post="virus replicationAntimicrob. Agents Chemother.1974646046410.1128/AAC.6.4.4604157345 165.NixonG.L.MossD.M.ShoneA.E.LallooD.G.FisherN.O’NeillP.M.WardS.A.BiaginiG.A.Antimalarial pharmacology and therapeutics of"/>
  <result pre="syndrome virus inhibitorsAntivir. Chem. Chemother.201725838910.1177/204020661774030329096526 164.BurdickJ.R.DurandD.P.Primaquine diphosphate: Inhibition of Newcastle" exact="disease" post="virus replicationAntimicrob. Agents Chemother.1974646046410.1128/AAC.6.4.4604157345 165.NixonG.L.MossD.M.ShoneA.E.LallooD.G.FisherN.O’NeillP.M.WardS.A.BiaginiG.A.Antimalarial pharmacology and therapeutics of"/>
  <result pre="in vitroArch. Virol.201415971171810.1007/s00705-013-1880-724142271 169.RothanH.A.BahraniH.MohamedZ.TeohT.C.ShankarE.M.RahmanN.A.YusofR.A combination of doxycycline and ribavirin alleviated" exact="chikungunya" post="infectionPLoS ONE201510e012636010.1371/journal.pone.012636025970853 170.WuZ.C.WangX.WeiJ.C.LiB.B.ShaoD.H.LiY.M.LiuK.ShiY.Y.ZhouB.QiuY.F.et al.Antiviral activity of doxycycline against vesicular"/>
  <result pre="chikungunya infectionPLoS ONE201510e012636010.1371/journal.pone.012636025970853 170.WuZ.C.WangX.WeiJ.C.LiB.B.ShaoD.H.LiY.M.LiuK.ShiY.Y.ZhouB.QiuY.F.et al.Antiviral activity of doxycycline against vesicular" exact="stomatitis" post="virus in vitroFEMS Microbiol. Lett.201536210.1093/femsle/fnv195 171.NgH.H.NarasarajuT.PhoonM.C.SimM.K.SeetJ.E.ChowV.T.Doxycycline treatment attenuates acute"/>
  <result pre="vesicular stomatitis virus in vitroFEMS Microbiol. Lett.201536210.1093/femsle/fnv195 171.NgH.H.NarasarajuT.PhoonM.C.SimM.K.SeetJ.E.ChowV.T.Doxycycline treatment attenuates" exact="acute" post="lung injury in mice infected with virulent influenza H3N2"/>
  <result pre="overlapping resonance Rayleigh scatteringSpectrochim. Acta A Mol. Biomol. Spectrosc.201412423724210.1016/j.saa.2013.12.11424486868 173.PolatK.Y.TosunM.S.ErtekinV.AydinliB.EmreS.Brucella" exact="infection" post="with pancytopenia after pediatric liver transplantationTranspl. Infect. Dis.20121432632910.1111/j.1399-3062.2011.00709.x22260451 174.WalterM.S.FrankM.J.SatuéM.MonjoM.RønoldH.J.LyngstadaasS.P.HaugenH.J.Bioactive"/>
  <result pre="Rayleigh scatteringSpectrochim. Acta A Mol. Biomol. Spectrosc.201412423724210.1016/j.saa.2013.12.11424486868 173.PolatK.Y.TosunM.S.ErtekinV.AydinliB.EmreS.Brucella infection with" exact="pancytopenia" post="after pediatric liver transplantationTranspl. Infect. Dis.20121432632910.1111/j.1399-3062.2011.00709.x22260451 174.WalterM.S.FrankM.J.SatuéM.MonjoM.RønoldH.J.LyngstadaasS.P.HaugenH.J.Bioactive implant surface"/>
  <result pre="and induces apoptosis of both human papillomavirus positive and negative" exact="cervical cancer" post="cell linesCan. J. Physiol. Pharmacol.20169452653310.1139/cjpp-2015-048126913972 178.YangJ.M.ChenY.F.TuY.Y.YenK.R.YangY.L.Combinatorial computational approaches to"/>
  <result pre="induces apoptosis of both human papillomavirus positive and negative cervical" exact="cancer" post="cell linesCan. J. Physiol. Pharmacol.20169452653310.1139/cjpp-2015-048126913972 178.YangJ.M.ChenY.F.TuY.Y.YenK.R.YangY.L.Combinatorial computational approaches to"/>
  <result pre="throughput in silico virtual screeningPLoS ONE20105e1012610.1371/journal.pone.001012620405039 183.AngiusF.PirasE.UdaS.MadedduC.SerpeR.BigiR.ChenW.DittmerD.P.PompeiR.IngianniA.Antimicrobial sulfonamides clear latent" exact="Kaposi sarcoma" post="herpesvirus infection and impair MDM2-p53 complex formationJ. Antibiot.20177096296610.1038/ja.2017.6728611469 184.CaselliE.GalvanM.SantoniF.AlvarezS.de"/>
  <result pre="in silico virtual screeningPLoS ONE20105e1012610.1371/journal.pone.001012620405039 183.AngiusF.PirasE.UdaS.MadedduC.SerpeR.BigiR.ChenW.DittmerD.P.PompeiR.IngianniA.Antimicrobial sulfonamides clear latent Kaposi" exact="sarcoma" post="herpesvirus infection and impair MDM2-p53 complex formationJ. Antibiot.20177096296610.1038/ja.2017.6728611469 184.CaselliE.GalvanM.SantoniF.AlvarezS.de"/>
  <result pre="virtual screeningPLoS ONE20105e1012610.1371/journal.pone.001012620405039 183.AngiusF.PirasE.UdaS.MadedduC.SerpeR.BigiR.ChenW.DittmerD.P.PompeiR.IngianniA.Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus" exact="infection" post="and impair MDM2-p53 complex formationJ. Antibiot.20177096296610.1038/ja.2017.6728611469 184.CaselliE.GalvanM.SantoniF.AlvarezS.de LeraA.R.IvanovaD.GronemeyerH.CarusoA.GuidoboniM.CassaiE.et al.Retinoic"/>
  <result pre="acid analogues inhibit human herpesvirus 8 replicationAntivir. Ther.20081319920918505171 185.KrugL.T.PozharskayaV.P.YuY.InoueN.OffermannM.K.Inhibition of" exact="infection" post="and replication of human herpesvirus 8 in microvascular endothelial"/>
  <result pre="cells by alpha interferon and phosphonoformic acidJ. Virol.2004788359837110.1128/JVI.78.15.8359-8371.200415254208 186.TselisA.Evidence for" exact="viral" post="etiology of multiple sclerosisSemin. Neurol.20113130731610.1055/s-0031-128765621964847 187.BuckwoldV.E.BeerB.E.DonisR.O.Bovine viral diarrhea virus"/>
  <result pre="Virol.2004788359837110.1128/JVI.78.15.8359-8371.200415254208 186.TselisA.Evidence for viral etiology of multiple sclerosisSemin. Neurol.20113130731610.1055/s-0031-128765621964847 187.BuckwoldV.E.BeerB.E.DonisR.O.Bovine" exact="viral" post="diarrhea virus as a surrogate model of hepatitis C"/>
  <result pre="186.TselisA.Evidence for viral etiology of multiple sclerosisSemin. Neurol.20113130731610.1055/s-0031-128765621964847 187.BuckwoldV.E.BeerB.E.DonisR.O.Bovine viral" exact="diarrhea" post="virus as a surrogate model of hepatitis C virus"/>
  <result pre="Neurol.20113130731610.1055/s-0031-128765621964847 187.BuckwoldV.E.BeerB.E.DonisR.O.Bovine viral diarrhea virus as a surrogate model of" exact="hepatitis" post="C virus for the evaluation of antiviral agentsAntivir. Res.20036011510.1016/S0166-3542(03)00174-814516916"/>
  <result pre="against a model member of the Flaviviridae family, the bovine" exact="viral" post="diarrhoea virus (BVDV)Planta Med.2006721169117410.1055/s-2006-94719816902856 Figure 1 Chemical structures of"/>
  <result pre="trials for the evaluation of the activity of antimalarials on" exact="viral" post="infections in patients. Virus Family Virus Species Drug Trial"/>
  <result pre="for the evaluation of the activity of antimalarials on viral" exact="infections" post="in patients. Virus Family Virus Species Drug Trial Number/Reference"/>
  <result pre="Chloroquine NCT00849602 Reduction in pain but not in length of" exact="disease" post="[36] CHIKV Chloroquine NCT003913131 No difference between CQ- and"/>
  <result pre="groups [37] Orthomyxoviridae IAV Chloroquine NCT01078779 No prevention of IAV" exact="infection" post="[38] Retroviridae HIV Hydroxychloroquine [39,40] Reduction in HIV-1 RNA"/>
  <result pre="[39,40] Reduction in HIV-1 RNA load in plasma Hydroxychloroquine ISRCTN30019040" exact="Increased" post="HIV-1 replication and decreased CD4 numbers [41] Chloroquine NCT00819390"/>
  <result pre="efficacy of Mefloquine (MQ) treatment and its combinations in JCPyV-infected" exact="progressive multifocal leukoencephalopathy" post="(PML) patients. Case Reports HIV Status Treatment Outcome References"/>
  <result pre="Mefloquine (MQ) treatment and its combinations in JCPyV-infected progressive multifocal" exact="leukoencephalopathy" post="(PML) patients. Case Reports HIV Status Treatment Outcome References"/>
  <result pre="No PML progression [122,123,124,125] Fatal outcome [126] Mefloquine + mirtazapine" exact="Premature" post="fatal outcome [127,128] Clinical Trial HIV negative versus HIV"/>
  <result pre="vivo studies for the assessment of antimalarial drug activity against" exact="viral infection." post="Virus Family Virus Species Drug Type of Study (Model)"/>
  <result pre="Clinical studies for the assessment of antimalarial drug activity against" exact="viral infection." post="Virus Family Virus Species Drug References Herpesviridae HCMV Artesunate"/>
 </snippets>
</snippetsTree>
